Document:

EX-4.13

 Exhibit 4.13 

2016 FREE SHARE PLAN 

REGULATION 2016 

 TABLE OF CONTENTS 

 

							
	 1.
	 	 Definitions
	  	 	3	 
	 2.
	 	 Shares Covered by Regulation 2016
	  			
	 3.
	 	 Administration of Regulation 2016
	  	 	5	 
	 4.
	 	 Limitations
	  	 	5	 
	 5.
	 	 Term of Regulation 2016
	  	 	6	 
	 6.
	 	 Free Share Award
	  	 	6	 
	 7.
	 	 Criteria and Conditions of Award
	  	 	6	 
	 8.
	 	 Calendar for the Free Share Award
	  	 	7	 
	 9.
	 	 Adjustments
	  	 	9	 
	 10.
	 	 Intervening Transactions
	  	 	10	 
	 11.
	 	 Amendment of Regulation 2016 – Management
	  	 	10	 
	 12.
	 	 Tax and Social Security Rules
	  	 	10	 
	 13.
	 	 Specific Restrictions and Information
	  	 	11	 
	 14.
	 	 Responsibility of the Company
	  	 	11	 
	 15.
	 	 Applicable Law, Jurisdiction
	  	 	11	 

  
 2 

 2016 FREE SHARE PLAN 

REGULATION 2016 
 Based on the
authorization granted by the combined general meeting on September 21, 2015 the Board of Directors of DBV Technologies (the “Company”) decided, at its meeting on April 6, 2016, in accordance with Articles L.225-197-1 to
L.225-197-5 of the Commercial Code, to adopt a regulation (“Regulation 2016”) for the purpose of awarding free shares in the Company to Eligible Persons (as defined below), which bylaw will govern the awarding of free shares, and
the terms and conditions of which are set out below. 
  

	1.	DEFINITIONS  

  

	(a)	“Share” means a share of the Company; 

  

	(b)	“Free Share Allocation” means the free share allocation on the terms and conditions set out in Regulation 2016; 

  

	(c)	“Shareholders’ Authorization” means the authorization to allocate shares free of charge granted to the Board of Directors by the shareholders of the Company at the extraordinary combined general
meeting on September 21, 2015; 

  
 3 

	(d)	“Beneficiary” means an Eligible Person to whom at least one Share has been allocated free of charge in accordance with Regulation 2016; 

 

	(e)	“Change of Control” means the completion of any transaction that has the effect of bringing about a change in the Control of the Company. The term “Control” has the meaning given to it
in Article L.233-3 of the Commercial Code; 

  

	(f)	“Award Date” means the date on which the Board of Directors grants the Free Share Allocation and constitutes the date on which the Acquisition Period commences; 

 

	(g)	“Eligible Person” means an officer (President, director general, or deputy director general of the Company) or employee of the Company or an Affiliated Company who meets the conditions set out in
Articles L.225-197-1 and L.225-197-2 of the Commercial Code and satisfies the conditions and criteria for the award established by the Board of Directors in its decision of April 6, 2016 and set out in Article 7 of Regulation 2016;

  

	(h)	“Manager” means the Board of Directors of the Company that administers Regulation 2016 in accordance with Article 3 of Regulation 2016; 

 

	(i)	“Disability” means a disability on the part of the Beneficiary that corresponds to classification in the second or third category provided in Article L.341-4 of the Social Security Code;

  

	(J)	“Regulation 2016” means this 2016 Free Share Plan as adopted by the Manager on April 6, 2016. 

  

	(k)	“Employee” means a natural person who is employed by the Company (or any Affiliated Company) and is subject to the power of control and direction of the employer entity in the performance and conduct of
the work to be carried out; 

  

	(l)	“Company” means DBV Technologies, a limited company incorporated under French law; 

  

	(m)	“Affiliated Company” means a company that meets the criteria set out in Article L.225-197-2 of the Commercial Code: 

 

	 	•	 	companies of which at least ten percent (10%) of the capital or voting rights are held, directly or indirectly, by the Company; 

 

	 	•	 	companies that hold, directly or indirectly, at least ten percent (10%) of the capital or voting rights of the Company; and 

  

	 	•	 	companies of which at least fifty percent (50%) of the capital or voting rights are held, directly or indirectly, by a company that itself holds, directly or indirectly, at least fifty percent (50%) of the
capital or voting rights of the Company. 

  
 4 

	2.	SHARES COVERED BY REGULATION 2016  

 According with the Shareholders’ Authorization, the
board of directors decided to allocate 271,750 Free Shares during the April 6, 2016 meeting to the beneficiaries listed in the minutes of the meeting. The number of Free Shares allocated by the Company, taking into account all of the previous Free
Shares Plans, remains below 10% of the share capital. 
  

	3.	ADMINISTRATION OF REGULATION 2016  

  

	 	(a)	Administration 

 Regulation 2016 will be administered by the Manager. 

 

	 	(b)	Powers of the Manager 

 Within the limits of the Commercial Code, the Shareholders’ Authorization
and Regulation 2016, the Manager will have discretion to: 
  

	 	i.	determine the Eligible Persons to whom Shares will be allocated free of charge and decide the number of bonus Shares to be awarded to each of them; 

 

	 	ii.	determine the terms and conditions of any Free Share Allocation; 

  

	 	iii.	analyze and interpret the terms of Regulation 2016; 

  

	 	iv.	decide to change or cancel any rule in Regulation 2016, within the limits prescribed by law; 

  

	 	v.	make any necessary or advisable decision in the course of executing Regulation 2016. 

  

	 	(c)	Effects of Decisions of the Manager 

 The decisions and interpretations of the Manager are final and
binding on all Beneficiaries. 
  

	4.	LIMITATIONS  

  

	(a)	The Shares allocated free of charge are governed by Articles L.225-197-1 to L.225-197-5 of the Commercial Code. They do not in any way constitute a component of the contract of employment or office or compensation of
the Beneficiary. 

 Neither Regulation 2016 nor any Share allocated free of charge confers a right on the Beneficiary to
remain in employment in the Company or an Affiliated Company, or in office in the Company. Moreover, they do not in any event limit the right that the Beneficiary, the Company, or an Affiliated Company, as the case may be, may have to terminate such
employment or office in any circumstance, with or without cause. 
  

	(b)	In accordance with Article L.225-197-1 of the Commercial Code, no Share may be allocated free of charge to an Eligible Person who, at the time of allocation the Share, directly holds more than 10% of the capital of the
Company, or for whom the effect of the award would be to increase his/her participation to more than 10% of the capital of the Company. 

  
 5 

	5.	TERM OF REGULATION 2016  

 Relying on the authorization and powers granted to it by the General
Shareholders’ Meeting on September 21, 2015, the Board of Directors, in its decision dated April 6, 2016, decided to adopt Regulation 2016, which came into effect on April 6, 2016. Unless it is cancelled early in accordance with the provisions
of Article 11, Regulation 2016 will remain in effect until the expiration of the Retention Period for the last Share allocated free of charge. 
  

	6.	FREE SHARE AWARD  

  

	 	(a)	Decision to award 

 The Manager decided during the Board of Directors meeting dated on April 6, 2016, to
allocate 271,750 Shares free of charge to the new DBV Technologies S.A.’s employees according a fixed ratio.
  

	 	(b)	Award of Shares and Acceptance by Beneficiaries 

 Each Eligible Person will be informed of the Free Share
Allocation by a notification letter setting out, in particular, (i) the number of Shares allocated free of charge to him/her, (ii) the term of the Acquisition Period, (iii) the term of the Retention Period, (iv) the conditions
and criteria to be met in order for the award to become definitive at the end of the Acquisition Period, and (v) any obligation imposed on him/her. A copy of Regulation 2016 will be attached to the notification letter. A sample notification
letter is set out in an Appendix to Regulation 2016. 
 The notification letter will be sent to the Beneficiary by registered mail with acknowledgement of
receipt or delivered by hand to the Beneficiary by the Manager or by any duly authorized person, and the Beneficiary will acknowledge receipt. 
 In the
event that the Beneficiary would like to take up the Free Share Allocation, he/she must make his/her acceptance known to the Company by sending the second copy of the notification of the Free Share Allocation to the Company, addressed to the
Manager, by registered mail with acknowledgement of receipt or by hand, signed by him/her under the notation “Good for acceptance,” within thirty (30) days of receipt of the notification of the Free Share Allocation. 

Otherwise, the Free Share Allocation will be null and void. 

Acceptance of Regulation 2016 by a Beneficiary constitutes acceptance of all of its terms. 

 

	7.	CRITERIA AND CONDITIONS OF AWARD  

 The Share award presumes that each Beneficiary meets the
following conditions and criteria, which were decided by the Board of Directors in its decision dated April 6, 2016, and which have been brought to the attention of the Beneficiaries by individual letter: 

 

	 	•	 	the Beneficiary must continue to be an Eligible Person throughout the entire Acquisition Period. 

  
 6 

	 	•	 	Share awards will be definitive only on the condition that the following performance criteria are met: 

  

	 	•	 	one third of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase III
‘PEPITES’ trial of Viaskin Peanut; 

  

	 	•	 	one third of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase II
‘MILES’ trial of Viaskin Milk; 

  

	 	•	 	one third of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the beginning of clinical testing of another product
candidate from the Viaskin platform. 

  

	8.	CALENDAR FOR THE FREE SHARE AWARD  

  

	 	(a)	Acquisition Period 

 The Free Share Allocation to Beneficiaries will become definitive only at the end of
an Acquisition Period of a minimum of two (2) years from the allocation date, or, on the terms set out in Article 7, on the condition that, throughout the entire Acquisition Period, the Beneficiary has continued to be an Eligible Person. 

In accordance with Article L.225-197-3 of the Commercial Code, the rights resulting from the Free Share Allocation may not be assigned or transferred by any
method whatsoever until the end of the Acquisition Period. However, in the event of the death of the beneficiary, his/her heirs may request that the shares be awarded within six months from the date of death. 

The definitive award is subject to an attendance requirement that is determined in accordance with the precise terms and conditions below. In order to be
Eligible, beneficiaries must therefore have a relationship with the Company or an Affiliated Company, throughout the entire Acquisition Period, by virtue of an office and/or a contract of employment. 

Accordingly, in the event of resignation, voluntary or involuntary retirement, termination of the Beneficiary’s contract of employment by mutual
agreement with the company concerned, dismissal, removal, or non-renewal of the Beneficiary’s office, during the Acquisition Period, for any cause whatsoever, the Beneficiary would, unless otherwise first decided by the Manager, lose all rights
to the Free Share Allocation and could make no claim for compensation in that regard. 
  

	 	•	 	Dismissal of the Beneficiary and/or removal and/or non-renewal of the Beneficiary’s offices during the Acquisition Period:  

 

	 	•	 	If the Beneficiary has only a contract of employment, the loss of the right to the Free Share Allocation will take place on the date of receipt (or first presentation) of the letter of notification of dismissal,
notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by the beneficiary of his/her dismissal and/or the reasons for the dismissal, and (iii) any judicial decision setting aside the dismissal.

  
 7 

	 	•	 	If the Beneficiary has only an office, the loss of the right to the Free Share Allocation will take place on the date of the meeting of the corporate body at which the removal was decided or the Beneficiary was
replaced as the office holder, if the beneficiary is a member of it, and if the Beneficiary is not a member of it, as of the date on which notice of the decision is received by the Beneficiary, notwithstanding (i) any notice requirement,
whether or not it has been given; (ii) any dispute by the beneficiary of his/her removal and/or the reasons for the removal, and (iii) any judicial decision setting aside the removal. 

 

	 	•	 	If the Beneficiary has both a contract of employment and an office and, in the event of the simultaneous or successive loss of both positions, the loss of the right to the Free Share Allocation will take place on
the date of receipt of the latter of the two notices referred to in the two preceding paragraphs. 

  

	 	•	 	Resignation during the Acquisition Period:  

 In the event of the resignation of the Beneficiary from
his/her position as an employee, if the Beneficiary is an employee only, or as an officer, if the Beneficiary is an officer only, or in the event of simultaneous or successive resignation from his/her position as an employee and as an officer, in
the event that the Beneficiary holds both positions at the same time, the loss of the right to the Free Share Allocation will take place: 
  

	 	•	 	if the Beneficiary is only an employee or an officer, on the date of receipt by the Company of the Beneficiary’s letter of resignation or on the date on which it is delivered by hand to an authorized
representative of the Company that employs him/her; and 

  

	 	•	 	if the Beneficiary holds positions as both an employee and an officer, the date of receipt by the Company of the first of the letters of resignation, or the date on which it is delivered by hand to an authorized
representative of the Company that employs him/her. 

 notwithstanding any notice requirement, whether or not it has been given. 

 

	 	•	 	Mutual agreement between the Beneficiary and the company that employs him/her during the Acquisition Period: 

In the event of termination of the contract of employment by mutual agreement between the Beneficiary and the company that employs him/her (including in the
case of contractual termination) if the Beneficiary is only an employee, or in the case of termination of the contract of employment by mutual agreement between the Beneficiary and the company that employs him/her and the simultaneous or successive
resignation or removal from his/her office, in the event that the Beneficiary holds both positions at the same time, the Beneficiary would lose his/her right to the Free Share Allocation on the first date on which the agreement terminating the
Beneficiary’s position as an employee is signed (or on which the agreement relating to the contractual termination is made), or the date of receipt of the notification of removal from office or the date of resignation from office. 

  
 8 

	 	•	 	Retirement of the Beneficiary during the Acquisition Period;  

 In the event that the Beneficiary retires
during the Acquisition Period, the Beneficiary will lose his/her right to the Free Share Allocation on the date of retirement. 
 However, by exception to
the foregoing: 
  

	(i)	in the event of the involuntary retirement of the Beneficiary at the initiative of the company that employs him/her during the Acquisition Period, in accordance with the applicable statutory and regulatory requirements,
the Beneficiary will retain his/her right to the Free Share Allocation, on the condition that he/she adheres to the Acquisition Period; 

  

	(ii)	in the event of the death of the Beneficiary during the Acquisition Period, his/her heirs may request the Free Share Allocation within six (6) months of the death; 

 

	(iii)	in the event of disability, the Beneficiary may request that the Shares be awarded within six (6) months of the event that resulted in the disability. 

It is specified that during the Acquisition Period, the Beneficiaries are not the owners of the Shares and have no shareholder’s rights. In particular,
they do not have the right to dividends, the right to vote, or the right to the information communicated to shareholders attached to the Shares. 
  

	 	(b)	Delivery of the Shares 

 At the end of the Acquisition Period, the Company will, on the condition that
the Beneficiary has adhered to the conditions and criteria of acquisition set out in Article 7 above, transfer to the Beneficiary the number of Shares decided by the Board of Directors. 

The shares awarded will immediately be treated in the same manner as the existing shares and will carry immediate dividend rights. 

 

	 	(c)	No Share Retention Period 

 As soon as free shares vest to the beneficiaries they may be sold, subject to
the regulations governing companies whose shares are traded on a regulated market. Free shares allocated to the beneficiaries are new ordinary shares and will immediately have the same rights as existing shares. 

 

	9.	ADJUSTMENTS  

 The Manager will be the only person with authority to decide, where applicable, the
conditions on which the number of bonus Shares awarded will be adjusted in the event of transactions involving the capital of the Company in order to preserve the rights of the Beneficiaries of the said Free Share Allocations. 

  
 9 

	10.	INTERVENING TRANSACTIONS  

  

	(a)	Take over of control 

 In the event of a takeover of control and by derogation from the provisions of
Articles 7 and 8 of this regulation, the beneficiaries will remain eligible for the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the
takeover and the last day of the vesting period. In this specific case, the shares will vest with no requirement to wait for the plan’s performance criteria to be met. 
  

	(b)	Exchange of Shares 

 In the event of an exchange of shares resulting from a merger or split carried out
in accordance with the regulations in force during the acquisition period, the provisions of this Article and, in particular, the above-mentioned periods, for the times remaining to run on the date of the exchange, will continue to be applicable to
the rights to the award and the shares received in exchange. 
  

	11.	AMENDMENT OF REGULATION 2016 - MANAGEMENT  

  

	 	(a)	Amendment 

 The Manager may, at any time, amend the provisions of, suspend, or terminate Regulation 2016,
on the condition that it is done in compliance with the law. 
  

	 	(b)	Consequences of Amendment or Cancellation 

 No amendment, alteration, suspension, or cancellation of
Regulation 2016 may reduce the rights of a Beneficiary without his/her agreement, unless such amendment results from a legislative or regulatory provision that has newly come into force or from any other provision that has executory effect and is
mandatory for the Company or an Affiliated Company. 
  

	 	(c)	Management 

 The management of Regulation 2016 is assigned to the Manager. However, the Manager reserves
the ability to assign the management of Regulation 2016 to any financial institution. The Manager will inform the Beneficiaries by registered letter with acknowledgement of receipt or delivery by hand specifying the name and contact information of
the financial institution chosen by the Manager to handle the management of Regulation 2016. 
  

	12.	TAX AND SOCIAL SECURITY RULES  

 The Beneficiary will bear the cost of all taxes and mandatory
deductions for which he/she is responsible under the tax regulations in force on the date on which the taxes or deductions become payable. 
 The
Beneficiary is invited to obtain advice about his/her own personal tax situation, in particular in order to be aware of the tax and social security treatment that will apply to him/her, and the Beneficiary declares that he/she is not in any way
relying on any tax or social security advice given by the Company. 

  
 10 

	13.	SPECIFIC RESTRICTIONS AND INFORMATION  

 Any person who holds shares of a company must, in
general, abstain from transferring them, acquiring new shares, or giving advice concerning those shares if he/she is in possession of information that could have a significant influence on the market price of the company that has not been made
public. Persons who violate those rules may be subject to penal and financial sanctions. Those rules apply to Eligible Persons who receive Shares. 
 We
invite you to refer to the Code of Ethics adopted by the Company that is online on the Intranet. 
 Moreover, in accordance with Article L.225-197-1 I
of the Commercial Code, the Shares may not be assigned or transferred after the expiration of the Retention Period: 
  

	 	•	 	within ten (10) trading sessions preceding and three (3) trading sessions following the date on which the consolidated accounts or, if none, the annual accounts are made public; 

 

	 	•	 	within the time between the date on which the corporate bodies of the Company have knowledge of information that, if it were made public, could have a significant impact on the market price of the Company’s shares,
and the date ten (10) trading sessions before the date on which the information is made public. 

 A calendar of publications is
distributed annually and is accessible online on the Intranet. 
 In accordance with the provisions of Article L.621-18-2 of the Monetary and Financial
Code, the transfer of shares by an officer or any person who has, within the Company, (i) the power to make management decisions concerning the Company’s activities and strategy, and (ii) regular access to privileged information
concerning the Company directly or indirectly requires that information be provided to the Autorité des Marchés Financiers [financial markets authority], with a copy to the Company, within the time allowed by the regulations in force.

  

	15.	RESPONSIBILITY OF THE COMPANY  

 The Company and its Affiliated Companies may not, in any way, be
held liable if, for any reason whatsoever not attributable to the Company or its Affiliated Companies, a Beneficiary was not able to acquire the Shares awarded to him/her. 
  

	16.	APPLICABLE LAW, JURISDICTION  

 Regulation 2016 is governed by French law and in particular by the
provisions of Articles L.225-197-1 et seq. of the Commercial Code. 
 Any dispute relating to Regulation 2016 will be within the exclusive
jurisdiction of the court of competent jurisdiction subject to the jurisdiction of the court of appeal in the place in which the head office of the Company is located. 

The Free Share Allocation under Regulation 2016 authorizes the Society, at any time, to ask the Beneficiary to comply with any legislative and regulatory
provision governing the Shares. 
 *        *        * 

* 

  
 11 

 APPENDIX 

SAMPLE NOTIFICATION LETTER CONCERNING DBV TECHNOLOGIES FREE SHARE ALLOCATION 

Limited company with share capital of 24,313,453 Euros 

Head office: 177/181 avenue Pierre Brossollette 92 120 Montrouge 

441 772 522 RCS Nanterre 

Montrouge, [date] 

[Name of Beneficiary] 
 Dear
Sir/Madam: 
 We are pleased to inform you that the Board of Directors of the Company has decided to allocate free shares of the Company to you in
accordance with the provisions of the regulation governing the free share plan, a copy of which is attached in an Appendix (“Regulation 2016”). 

The terms that are not defined in this letter and that are capitalized have the meaning assigned to them in Regulation 2016. 

These free Shares have been awarded under the provisions of Articles L.225-197-1 to L.225-197-5 of the Commercial Code. 

Under the decision of the Board of Directors, you were awarded
[                    ] ([                    ])
free shares of the Company, on [                    ], on the terms set out below. 

	1.	Acquisition Period and conditions 

 The definitive share award will be subject to the following
performance conditions: 
  

	 	•	 	one third of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase III
‘PEPITES’ trial for Viaskin Peanut; 

  

	 	•	 	one third of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase II
‘MILES’ trial of Viaskin Milk; 

  

	 	•	 	one third of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the beginning of clinical testing of another product
candidate from the Viaskin platform. 

  

	2.	Conditions and criteria of allocation 

 The Free Share Allocation assumes that during the
Acquisition Period referred to above, you will meet the following conditions and criteria: 
 You must, throughout the Acquisition Period, have a
relationship with the Company or an Affiliated Company under an office and/or a contract of employment. 
 In the event of resignation, voluntary or
involuntary retirement, termination of the contract of employment by mutual agreement, dismissal, removal, or termination of the office, during the Acquisition Period, for any reason whatsoever, you will lose all right to the Free Share Allocation
and may claim no compensation in that regard. 
 In the event of resignation, the loss of the right to the Free Share Allocation will occur on the date of
receipt by the Company or the Affiliated Company concerned of your letter of resignation or on the date of delivery by hand of the letter to an authorized representative of the company that employs you, notwithstanding any notice requirement,
whether or not it has been given. 
 In the event of dismissal or removal, the loss of the right to the Free Share Allocation will occur on the date of
receipt (or first presentation) of the letter of notification of dismissal or removal, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by you of your dismissal and/or the reasons for the
dismissal, and (iii) any judicial decision setting aside the dismissal. 
 However, by exception to the foregoing, 

 

	(i)	in the event of retirement or dismissal for economic reasons during the Acquisition Period, you will retain your right to the Free Share Allocation; 

 

	(ii)	in the event of death during the Acquisition Period, your heirs may request the Free Share Allocation within six (6) months of the date of your death. 

 

	(iii)	in the event disability during the Acquisition Period, you may request the Free Share Allocation within six (6) months of the date of your disability. 

	(iv)	In the event of a takeover of control within the meaning of Article L. 233-3 of the French Commercial Code of DBV Technologies by any person acting alone or in concert with other persons, the beneficiaries will remain
eligible for the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the takeover and the last day of the vesting period. In this specific case,
the shares will vest with no requirement to wait for the plan’s performance criteria to be met. 

 At the end of the Acquisition Period,
and on the condition that the criteria set out above have been met, the Company will transfer to you the [                    ]
([                    ]) Shares referred to above in a specific securities account you have mentioned. 

You should contact a Bank (including “Banque Transatlantique”) in order to open such securities account. 

Accordingly, you will become a shareholder of the Company on that date, Shares will become available and may, in particular, be freely transferred as the 2016
Free Shares Plan has no retention period. 
 Your acceptance of the Free Share Allocation on the terms set out above constitutes acceptance of the terms of
Bylaw 2016. 
 In the event that you accept the Free Share Allocation, we would appreciate it if you would sign two copies of this notification of Free
Share Allocation and keep one copy and return the other to the Company by registered letter or delivered by hand in a period of 30 days from the receipt of this letter. Otherwise, the award will be void. 

 

	
	Sincerely yours,
	
	Pierre-Henri Behnamou

  

	
	Good for acceptance
	
	[Name of Beneficiary]
	
	Encl.: Regulation 2016

 2016-2 FREE SHARE PLAN 

REGULATION 

 TABLE OF CONTENTS 

 

							
	 1.
	 	 Definitions
	  	 	3	 
	 2.
	 	 Shares Covered by Regulation 2016-2
	  	 	5	 
	 3.
	 	 Administration of Regulation 2016-2
	  	 	5	 
	 4.
	 	 Limitations
	  	 	5	 
	 5.
	 	 Term of Regulation 2016-2
	  	 	6	 
	 6.
	 	 Free Shares Award
	  	 	6	 
	 7.
	 	 Criteria and Conditions of Award
	  	 	6	 
	 8.
	 	 Calendar for the Free Share Award
	  	 	7	 
	 9.
	 	 Adjustments
	  	 	9	 
	 10.
	 	 Intervening Transactions
	  	 	10	 
	 11.
	 	 Amendment of Regulation 2016 – Management
	  	 	10	 
	 12.
	 	 Tax and Social Security Rules
	  	 	10	 
	 13.
	 	 Specific Restrictions and Information
	  	 	11	 
	 14.
	 	 Responsibility of the Company
	  	 	11	 
	 15.
	 	 Applicable Law, Jurisdiction
	  	 	11	 

  
 2 

 2016 FREE SHARE PLAN 

REGULATION 2016 
 Based on the
authorization granted by the combined general meeting on September 21, 2015 the Board of Directors of DBV Technologies (the “Company”) decided, at its meeting on October 27, 2016, in accordance with Articles L.225-197-1 to
L.225-197-5 of the Commercial Code, to adopt a regulation (“2016-2 FREE SHARE Regulation”) for the purpose of awarding free shares in the Company to Eligible Persons (as defined below), which bylaw will govern the awarding of free
shares, and the terms and conditions of which are set out below. 
  

	1.	DEFINITIONS  

  

	(a)	“Share” means a share of the Company; 

  

	(b)	“Free Share Allocation” means the free share allocation on the terms and conditions set out in Regulation 2016-2; 

  

	(c)	“Shareholders’ Authorization” means the authorization to allocate shares free of charge granted to the Board of Directors by the shareholders of the Company at the extraordinary combined general
meeting on September 21 2015; 

  
 3 

	(d)	“Beneficiary” means an Eligible Person to whom at least one Share has been allocated free of charge in accordance with Regulation 2016-2; 

 

	(e)	“Change of Control” means the completion of any transaction that has the effect of bringing about a change in the Control of the Company. The term “Control” has the meaning given to it
in Article L.233-3 of the Commercial Code; 

  

	(f)	“Award Date” means the date on which the Board of Directors grants the Free Share Allocation and constitutes the date on which the Acquisition Period commences; 

 

	(g)	“Eligible Person” means an officer (President, director general, or deputy director general of the Company) or employee of the Company or an Affiliated Company who meets the conditions set out in
Articles L.225-197-1 and L.225-197-2 of the Commercial Code and satisfies the conditions and criteria for the award established by the Board of Directors in its decision of October 27, 2016 and set out in Article 7 of Regulation 2016-2;

  

	(h)	“Manager” means the Board of Directors of the Company that administers Regulation 2016-2 in accordance with Article 3 of Regulation 2016-2; 

 

	(i)	“Disability” means a disability on the part of the Beneficiary that corresponds to classification in the second or third category provided in Article L.341-4 of the Social Security Code;

  

	(J)	“Regulation 2016-2” means this 2016 Free Share Plan as adopted by the Manager on October 27, 2016. 

  

	(k)	“Employee” means a natural person who is employed by the Company (or any Affiliated Company) and is subject to the power of control and direction of the employer entity in the performance and conduct of
the work to be carried out; 

  

	(l)	“Company” means DBV Technologies, a limited company incorporated under French law; 

  

	(m)	“Affiliated Company” means a company that meets the criteria set out in Article L.225-197-2 of the Commercial Code: 

 

	 	•	 	companies of which at least ten percent (10%) of the capital or voting rights are held, directly or indirectly, by the Company; 

 

	 	•	 	companies that hold, directly or indirectly, at least ten percent (10%) of the capital or voting rights of the Company; and 

  

	 	•	 	companies of which at least fifty percent (50%) of the capital or voting rights are held, directly or indirectly, by a company that itself holds, directly or indirectly, at least fifty percent (50%) of the
capital or voting rights of the Company. 

  
 4 

	2.	SHARES COVERED BY REGULATION 2016-2 

 According with the Shareholders’ Authorization, the
board of directors will decide to allocate Free Shares during its meeting to the beneficiaries listed in the minutes of the Board meeting. The number of Free Shares allocated by the Company, will consider all the previous Free Shares Plans, remains
below 10% of the share capital. 
  

	3.	ADMINISTRATION OF REGULATION 2016-2 

  

	 	(a)	Administration 

 Regulation 2016-2 will be administered by the Manager. 

 

	 	(b)	Powers of the Manager 

 Within the limits of the Commercial Code, the Shareholders’ Authorization
and Regulation 2016-2, the Manager will have discretion to: 
  

	 	i.	determine the Eligible Persons to whom Shares will be allocated free of charge and decide the number of bonus Shares to be awarded to each of them; 

 

	 	ii.	determine the terms and conditions of any Free Share Allocation; 

  

	 	iii.	analyze and interpret the terms of Regulation 2016-2; 

  

	 	iv.	decide to change or cancel any rule in Regulation 2016-2, within the limits prescribed by law; 

  

	 	v.	make any necessary or advisable decision in the course of executing Regulation 2016-2. 

  

	 	(c)	Effects of Decisions of the Manager 

 The decisions and interpretations of the Manager are final and
binding on all Beneficiaries. 
  

	4.	LIMITATIONS  

  

	(a)	The Shares allocated free of charge are governed by Articles L.225-197-1 to L.225-197-5 of the Commercial Code. They do not in any way constitute a component of the contract of employment or office or compensation of
the Beneficiary. 

 Neither Regulation 2016-2 nor any Share allocated free of charge confers a right on the Beneficiary to
remain in employment in the Company or an Affiliated Company, or in office in the Company. Moreover, they do not in any event limit the right that the Beneficiary, the Company, or an Affiliated Company, as the case may be, may have to terminate such
employment or office in any circumstance, with or without cause. 
  

	(b)	In accordance with Article L.225-197-1 of the Commercial Code, no Share may be allocated free of charge to an Eligible Person who, at the time of allocation the Share, directly holds more than 10% of the capital of the
Company, or for whom the effect of the award would be to increase his/her participation to more than 10% of the capital of the Company. 

  
 5 

	5.	TERM OF REGULATION 2016-2 

 Relying on the authorization and powers granted to it by the General
Shareholders’ Meeting on September 21, 2015, the Board of Directors, in its decision dated October 27, 2016, decided to adopt Regulation 2016-2, which came into effect on October 27, 2016. Unless it is cancelled early in accordance with the
provisions of Article 11, Regulation 2016-2 will remain in effect until the expiration of the Retention Period for the last Share allocated free of charge. 
  

	6.	FREE SHARE AWARD  

  

	 	(a)	Decision to award 

 The Manager will decide during Board of Directors meetings to allocate free shares to
the new DBV Technologies S.A.’s employees according a fixed ratio.
  

	 	(b)	Award of Shares and Acceptance by Beneficiaries 

 Each Eligible Person will be informed of the Free Share
Allocation by a notification letter setting out, in particular, (i) the number of Shares allocated free of charge to him/her, (ii) the term of the Acquisition Period, (iii) the term of the Retention Period, (iv) the conditions
and criteria to be met in order for the award to become definitive at the end of the Acquisition Period, and (v) any obligation imposed on him/her. A copy of Regulation 2016-2 will be attached to the notification letter. A sample notification
letter is set out in an Appendix to Regulation 2016-2. 
 The notification letter will be sent to the Beneficiary by registered mail with acknowledgement of
receipt or delivered by hand to the Beneficiary by the Manager or by any duly authorized person, and the Beneficiary will acknowledge receipt. 
 In the
event that the Beneficiary would like to take up the Free Share Allocation, he/she must make his/her acceptance known to the Company by sending the second copy of the notification of the Free Share Allocation to the Company, addressed to the
Manager, by registered mail with acknowledgement of receipt or by hand, signed by him/her under the notation “Good for acceptance,” within thirty (30) days of receipt of the notification of the Free Share Allocation. 

Otherwise, the Free Share Allocation will be null and void. 

Acceptance of Regulation 2016-2 by a Beneficiary constitutes acceptance of all of its terms. 

 

	7.	CRITERIA AND CONDITIONS OF AWARD  

 The Share award presumes that each Beneficiary meets the
following conditions and criteria, which were decided by the Board of Directors in its decision dated October 27, 2016, and which have been brought to the attention of the Beneficiaries by individual letter: 

 

	 	•	 	the Beneficiary must continue to be an Eligible Person throughout the entire Acquisition Period. 

  
 6 

	 	•	 	Share awards will be definitive only on the condition that the following performance criteria are met: 

  

	 	•	 	half of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase III
‘PEPITES’ trial of Viaskin Peanut; 

  

	 	•	 	half of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase II
‘MILES’ trial of Viaskin Milk. 

  

	8.	CALENDAR FOR THE FREE SHARE AWARD  

  

	 	(a)	Acquisition Period 

 The Free Share Allocation to Beneficiaries will become definitive only at the end of
an Acquisition Period of a minimum of two (2) years from the allocation date, or, on the terms set out in Article 7, on the condition that, throughout the entire Acquisition Period, the Beneficiary has continued to be an Eligible Person. 

In accordance with Article L.225-197-3 of the Commercial Code, the rights resulting from the Free Share Allocation may not be assigned or transferred by any
method whatsoever until the end of the Acquisition Period. However, in the event of the death of the beneficiary, his/her heirs may request that the shares be awarded within six months from the date of death. 

The definitive award is subject to an attendance requirement that is determined in accordance with the precise terms and conditions below. In order to be
Eligible, beneficiaries must therefore have a relationship with the Company or an Affiliated Company, throughout the entire Acquisition Period, by virtue of an office and/or a contract of employment. 

Accordingly, in the event of resignation, voluntary or involuntary retirement, termination of the Beneficiary’s contract of employment by mutual
agreement with the company concerned, dismissal, removal, or non-renewal of the Beneficiary’s office, during the Acquisition Period, for any cause whatsoever, the Beneficiary would, unless otherwise first decided by the Manager, lose all rights
to the Free Share Allocation and could make no claim for compensation in that regard. 
  

	 	•	 	Dismissal of the Beneficiary and/or removal and/or non-renewal of the Beneficiary’s offices during the Acquisition Period:  

 

	 	•	 	If the Beneficiary has only a contract of employment, the loss of the right to the Free Share Allocation will take place on the date of receipt (or first presentation) of the letter of notification of dismissal,
notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by the beneficiary of his/her dismissal and/or the reasons for the dismissal, and (iii) any judicial decision setting aside the dismissal.

  
 7 

	 	•	 	If the Beneficiary has only an office, the loss of the right to the Free Share Allocation will take place on the date of the meeting of the corporate body at which the removal was decided or the Beneficiary was
replaced as the office holder, if the beneficiary is a member of it, and if the Beneficiary is not a member of it, as of the date on which notice of the decision is received by the Beneficiary, notwithstanding (i) any notice requirement,
whether or not it has been given; (ii) any dispute by the beneficiary of his/her removal and/or the reasons for the removal, and (iii) any judicial decision setting aside the removal. 

 

	 	•	 	If the Beneficiary has both a contract of employment and an office and, in the event of the simultaneous or successive loss of both positions, the loss of the right to the Free Share Allocation will take place on
the date of receipt of the latter of the two notices referred to in the two preceding paragraphs. 

  

	 	•	 	Resignation during the Acquisition Period:  

 In the event of the resignation of the Beneficiary from
his/her position as an employee, if the Beneficiary is an employee only, or as an officer, if the Beneficiary is an officer only, or in the event of simultaneous or successive resignation from his/her position as an employee and as an officer, in
the event that the Beneficiary holds both positions at the same time, the loss of the right to the Free Share Allocation will take place: 
  

	 	•	 	if the Beneficiary is only an employee or an officer, on the date of receipt by the Company of the Beneficiary’s letter of resignation or on the date on which it is delivered by hand to an authorized
representative of the Company that employs him/her; and 

  

	 	•	 	if the Beneficiary holds positions as both an employee and an officer, the date of receipt by the Company of the first of the letters of resignation, or the date on which it is delivered by hand to an authorized
representative of the Company that employs him/her. 

 notwithstanding any notice requirement, whether or not it has been given. 

 

	 	•	 	Mutual agreement between the Beneficiary and the company that employs him/her during the Acquisition Period: 

In the event of termination of the contract of employment by mutual agreement between the Beneficiary and the company that employs him/her (including in the
case of contractual termination) if the Beneficiary is only an employee, or in the case of termination of the contract of employment by mutual agreement between the Beneficiary and the company that employs him/her and the simultaneous or successive
resignation or removal from his/her office, in the event that the Beneficiary holds both positions at the same time, the Beneficiary would lose his/her right to the Free Share Allocation on the first date on which the agreement terminating the
Beneficiary’s position as an employee is signed (or on which the agreement relating to the contractual termination is made), or the date of receipt of the notification of removal from office or the date of resignation from office. 

  
 8 

	 	•	 	Retirement of the Beneficiary during the Acquisition Period;  

 In the event that the Beneficiary retires
during the Acquisition Period, the Beneficiary will lose his/her right to the Free Share Allocation on the date of retirement. 
 However, by exception to
the foregoing: 
  

	(i)	in the event of the involuntary retirement of the Beneficiary at the initiative of the company that employs him/her during the Acquisition Period, in accordance with the applicable statutory and regulatory requirements,
the Beneficiary will retain his/her right to the Free Share Allocation, on the condition that he/she adheres to the Acquisition Period; 

  

	(ii)	in the event of the death of the Beneficiary during the Acquisition Period, his/her heirs may request the Free Share Allocation within six (6) months of the death; 

 

	(iii)	in the event of disability, the Beneficiary may request that the Shares be awarded within six (6) months of the event that resulted in the disability. 

It is specified that during the Acquisition Period, the Beneficiaries are not the owners of the Shares and have no shareholder’s rights. In particular,
they do not have the right to dividends, the right to vote, or the right to the information communicated to shareholders attached to the Shares. 
  

	 	(b)	Delivery of the Shares 

 At the end of the Acquisition Period, the Company will, on the condition that
the Beneficiary has adhered to the conditions and criteria of acquisition set out in Article 7 above, transfer to the Beneficiary the number of Shares decided by the Board of Directors. 

The shares awarded will immediately be treated in the same manner as the existing shares and will carry immediate dividend rights. 

 

	 	(c)	No Share Retention Period 

 As soon as free shares vest to the beneficiaries they may be sold, subject to
the regulations governing companies whose shares are traded on a regulated market. Free shares allocated to the beneficiaries are new ordinary shares and will immediately have the same rights as existing shares. 

 

	9.	ADJUSTMENTS  

 The Manager will be the only person with authority to decide, where applicable, the
conditions on which the number of bonus Shares awarded will be adjusted in the event of transactions involving the capital of the Company in order to preserve the rights of the Beneficiaries of the said Free Share Allocations. 

  
 9 

	10.	INTERVENING TRANSACTIONS  

  

	(a)	Take over of control 

 In the event of a takeover of control and by derogation from the provisions of
Articles 7 and 8 of this regulation, the beneficiaries will remain eligible for the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the
takeover and the last day of the vesting period. In this specific case, the shares will vest with no requirement to wait for the plan’s performance criteria to be met. 
  

	(b)	Exchange of Shares 

 In the event of an exchange of shares resulting from a merger or split carried out
in accordance with the regulations in force during the acquisition period, the provisions of this Article and, in particular, the above-mentioned periods, for the times remaining to run on the date of the exchange, will continue to be applicable to
the rights to the award and the shares received in exchange. 
  

	11.	AMENDMENT OF REGULATION 2016-2 - MANAGEMENT  

  

	 	(a)	Amendment 

 The Manager may, at any time, amend the provisions of, suspend, or terminate Regulation
2016-2, on the condition that it is done in compliance with the law. 
  

	 	(b)	Consequences of Amendment or Cancellation 

 No amendment, alteration, suspension, or cancellation of
Regulation 2016-2 may reduce the rights of a Beneficiary without his/her agreement, unless such amendment results from a legislative or regulatory provision that has newly come into force or from any other provision that has executory effect and is
mandatory for the Company or an Affiliated Company. 
  

	 	(c)	Management 

 The management of Regulation 2016-2 is assigned to the Manager. However, the Manager
reserves the ability to assign the management of Regulation 2016-2 to any financial institution. The Manager will inform the Beneficiaries by registered letter with acknowledgement of receipt or delivery by hand specifying the name and contact
information of the financial institution chosen by the Manager to handle the management of Regulation 2016-2. 
  

	12.	TAX AND SOCIAL SECURITY RULES  

 The Beneficiary will bear the cost of all taxes and mandatory
deductions for which he/she is responsible under the tax regulations in force on the date on which the taxes or deductions become payable. 
 The
Beneficiary is invited to obtain advice about his/her own personal tax situation, in particular in order to be aware of the tax and social security treatment that will apply to him/her, and the Beneficiary declares that he/she is not in any way
relying on any tax or social security advice given by the Company. 

  
 10 

	13.	SPECIFIC RESTRICTIONS AND INFORMATION  

 Any person who holds shares of a company must, in
general, abstain from transferring them, acquiring new shares, or giving advice concerning those shares if he/she is in possession of information that could have a significant influence on the market price of the company that has not been made
public. Persons who violate those rules may be subject to penal and financial sanctions. Those rules apply to Eligible Persons who receive Shares. 
 We
invite you to refer to the Code of Ethics adopted by the Company that is online on the Intranet. 
 Moreover, in accordance with Article L.225-197-1 I
of the Commercial Code, the Shares may not be assigned or transferred after the expiration of the Retention Period: 
  

	 	•	 	within ten (10) trading sessions preceding and three (3) trading sessions following the date on which the consolidated accounts or, if none, the annual accounts are made public; 

 

	 	•	 	within the time between the date on which the corporate bodies of the Company have knowledge of information that, if it were made public, could have a significant impact on the market price of the Company’s shares,
and the date ten (10) trading sessions before the date on which the information is made public. 

 A calendar of publications is
distributed annually and is accessible online on the Intranet. 
 In accordance with the provisions of Article L.621-18-2 of the Monetary and Financial
Code, the transfer of shares by an officer or any person who has, within the Company, (i) the power to make management decisions concerning the Company’s activities and strategy, and (ii) regular access to privileged information
concerning the Company directly or indirectly requires that information be provided to the Autorité des Marchés Financiers [financial markets authority], with a copy to the Company, within the time allowed by the regulations in force.

  

	14.	RESPONSIBILITY OF THE COMPANY  

 The Company and its Affiliated Companies may not, in any way, be
held liable if, for any reason whatsoever not attributable to the Company or its Affiliated Companies, a Beneficiary was not able to acquire the Shares awarded to him/her. 
  

	15.	APPLICABLE LAW, JURISDICTION  

 Regulation 2016-2 is governed by French law and in particular by
the provisions of Articles L.225-197-1 et seq. of the Commercial Code. 
 Any dispute relating to Regulation 2016-2 will be within the exclusive
jurisdiction of the court of competent jurisdiction subject to the jurisdiction of the court of appeal in the place in which the head office of the Company is located. 

The Free Share Allocation under Regulation 2016-2 authorizes the Society, at any time, to ask the Beneficiary to comply with any legislative and regulatory
provision governing the Shares. 
 *        *        * 

* 

  
 11 

 APPENDIX 

SAMPLE NOTIFICATION LETTER CONCERNING DBV TECHNOLOGIES FREE SHARE ALLOCATION 

Limited company with share capital of 2,464,882.80 Euros 

Head office: 177/181 avenue Pierre Brossolette 92 120 Montrouge 

441 772 522 RCS Nanterre 

Montrouge, [date] 

[Name of Beneficiary] 
 Dear
Sir/Madam: 
 We are pleased to inform you that the Board of Directors of the Company has decided to allocate free shares of the Company to you in
accordance with the provisions of the regulation governing the free share plan, a copy of which is attached in an Appendix (“Regulation 2016-2”). 

The terms that are not defined in this letter and that are capitalized have the meaning assigned to them in Regulation 2016-2. 

These free Shares have been awarded under the provisions of Articles L.225-197-1 to L.225-197-5 of the Commercial Code. 

Under the decision of the Board of Directors, you were awarded
[                    ] ([                    ])
free shares of the Company, on [                    ], on the terms set out below. 

	1.	Acquisition Period and conditions 

 The definitive share award will be subject to the following
performance conditions: 
  

	 	•	 	half of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase III
‘PEPITES’ trial for Viaskin Peanut; 

  

	 	•	 	half of the Shares allocated will not vest until the later of the following two dates: (i) the end of the two (2) year Vesting Period and (ii) at the primary efficacy endpoint of the Phase II
‘MILES’ trial of Viaskin Milk. 

  

	2.	Conditions and criteria of allocation 

 The Free Share Allocation assumes that during the
Acquisition Period referred to above, you will meet the following conditions and criteria: 
 You must, throughout the Acquisition Period, have a
relationship with the Company or an Affiliated Company under an office and/or a contract of employment. 
 In the event of resignation, voluntary or
involuntary retirement, termination of the contract of employment by mutual agreement, dismissal, removal, or termination of the office, during the Acquisition Period, for any reason whatsoever, you will lose all right to the Free Share Allocation
and may claim no compensation in that regard. 
 In the event of resignation, the loss of the right to the Free Share Allocation will occur on the date of
receipt by the Company or the Affiliated Company concerned of your letter of resignation or on the date of delivery by hand of the letter to an authorized representative of the company that employs you, notwithstanding any notice requirement,
whether or not it has been given. 
 In the event of dismissal or removal, the loss of the right to the Free Share Allocation will occur on the date of
receipt (or first presentation) of the letter of notification of dismissal or removal, notwithstanding (i) any notice requirement, whether or not it has been given; (ii) any dispute by you of your dismissal and/or the reasons for the
dismissal, and (iii) any judicial decision setting aside the dismissal. 
 However, by exception to the foregoing, 

 

	(i)	in the event of retirement or dismissal for economic reasons during the Acquisition Period, you will retain your right to the Free Share Allocation; 

 

	(ii)	in the event of death during the Acquisition Period, your heirs may request the Free Share Allocation within six (6) months of the date of your death. 

 

	(iii)	in the event disability during the Acquisition Period, you may request the Free Share Allocation within six (6) months of the date of your disability. 

	(iv)	In the event of a takeover of control within the meaning of Article L. 233-3 of the French Commercial Code of DBV Technologies by any person acting alone or in concert with other persons, the beneficiaries will remain
eligible for the allocation at the end of the vesting period, even if their employment contract and/or corporate mandate is terminated, for any reason, between the date of the takeover and the last day of the vesting period. In this specific case,
the shares will vest with no requirement to wait for the plan’s performance criteria to be met. 

 At the end of the Acquisition Period,
and on the condition that the criteria set out above have been met, the Company will transfer to you the [                    ]
([                    ]) Shares referred to above in a specific securities account you have mentioned. 

You should contact a Bank (including “Banque Transatlantique”) in order to open such securities account. 

Accordingly, you will become a shareholder of the Company on that date, Shares will become available and may, in particular, be freely transferred as the
2016-2 Free Shares Plan has no retention period. 
 Your acceptance of the Free Share Allocation on the terms set out above constitutes acceptance of the
terms of Bylaw 2016-2. 
 In the event that you accept the Free Share Allocation, we would appreciate it if you would sign two copies of this notification
of Free Share Allocation and keep one copy and return the other to the Company by registered letter or delivered by hand in a period of 30 days from the receipt of this letter. Otherwise, the award will be void. 

 

	
	Sincerely yours,
	
	Pierre-Henri Behnamou

  

	
	Good for acceptance
	
	[Name of Beneficiary]
	
	Encl.: Regulation 2016EX-4.14

 Exhibit 4.14 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
 DEVELOPMENT COLLABORATION AND
LICENSE AGREEMENT 
 By and Between 

DBV TECHNOLOGIES 
 and

 NESTEC S.A. 

 DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT 

This DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (together with the exhibits hereto, this “Agreement”) is entered into on
this 27th day of May, 2016 (the “Effective Date”), by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland
(“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”). NESTEC and DBV may each be referred to herein individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, DBV controls proprietary technology for manufacturing an adhesive skin patch for delivery of proteins through intact skin (as
further defined below, the “Viaskin® Technology”) and is developing therapeutic products for the treatment of certain allergies and other product candidates in areas of unmet
medical need in immunotherapy using the Viaskin® Technology; 
 WHEREAS, DBV
has commercialized in France a ready to use and standardized atopy patch test for the diagnosis of cow’s milk protein allergy (“CMPA”), marketed under the trademark
Diallertest® (“Diallertest”), and DBV intends to discontinue commercialization of Diallertest; and 

WHEREAS, NESTEC desires to commercialize a diagnostic test for milk protein allergy, and the Parties have agreed to establish a
collaboration whereby DBV will develop a diagnostic test for CMPA using the Viaskin® Technology, and NESTEC will have an exclusive license to commercialize such diagnostic test worldwide,
subject to the terms and conditions of the Agreement. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual premises and covenants set forth in this Agreement and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I. 

DEFINITIONS 
 The following
terms as used in this Agreement shall have the meanings set forth in this ARTICLE I: 
 1.1 “Acquirer” means, any
Third Party (together with its Affiliates but excluding DBV and DBV’s Affiliates) that after the Effective Date either (a) acquires the control (within the meaning of article L.233-3 of the French Code de commerce) of DBV, or
(b) acquires all or substantially all of DBV’s assets or business going concern, in each (a) or (b) cases by any means whatsoever, securities purchase, merger, consolidation, contribution, spin off, sale of assets or business
going concern, or transfer to a trust (fiducie). 

  
 2 

 1.2 “Affiliate” means, with respect to a particular Person, any other Person
that directly or indirectly is controlled by, controls or is under common control with such Person as defined in article L. 233-3 of the French Code de commerce. 

1.3 “Anti-Bribery Laws” means the US Foreign Corrupt Practices Act, as amended (15 U.S.C. §§ 78dd-1, et. seq.), the
United Kingdom Bribery Act 2010 and all other similar laws throughout the Territories for prevention of providing inducements to government officials to obtain or retain business or gain an improper advantage. 

1.4 “Biosimilar/Generic Product” means a diagnostic test for CMPA which (i) is identical or highly similar to the
Licensed Product known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product, (ii) is registered and commercialized by a Third Party without any license or right by
NESTEC, its Affiliates or Sublicensees, and (iii) is approved for use pursuant to a regulatory approval process governing approval of generic, interchangeable or biosimilar biologics based on the then-current standards for regulatory approval,
whether or not such regulatory approval was based upon clinical data generated by the Parties pursuant to this Agreement or was obtained using an abbreviated, expedited or other process. 

1.5 “Business Day” means a day other than Saturday, Sunday or other day on which commercial banks in Paris, France and in
Vevey, Switzerland, are generally closed. 
 1.6 “Calendar Quarter” means the successive periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 or December 31, for so long as this Agreement is in effect. 

1.7 “Calendar Year” means any year beginning on January 1 and ending on December 31 of such year. 

1.8 “Clinical Trial” means a clinical study conducted on certain numbers of human subjects (depending on the phase of the
trial) that is designed to (a) establish that a product for the diagnosis of human diseases and conditions is reasonably safe for continued testing, (b) investigate the safety and efficacy of the product for its intended use, and to define
warnings, precautions and adverse reactions that may be associated with the product in the dosage range to be prescribed, and/or (c) support Regulatory Approval of such product or label expansion of such product, in accordance with 21 CFR Part
56, 21 CFR Part 50 and 21 CFR Part 812 and the equivalent requirements of a Regulatory Authority outside of the United States. 
 1.9
“CMC” or “Chemistry and Manufacturing Control” means pharmaceutical development covering all chemistry, manufacturing and controls activities, including manufacturing process scale up (including without limitation,
registration batches/process validation, engineering studies qualification and validation, process validation, characterization and stability, scale and technology transfer to contract manufacturing organizations), analytical methods, qualification
and validation activities, quality assurance/quality control development. 

  
 3 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.10 “CMP” means the following cow’s milk proteins: [***]. 

1.11 “CMPA” means cow’s milk protein allergy. 

1.12 “Commercialization” means all activities related to the commercial exploitation of products for the diagnosis of human
diseases and conditions, including importation, exportation, marketing, promotion, distribution, pre-launch, launch, sale, and offering for sale of such products, but excluding Manufacturing and Development activities, as well as any Clinical
Trials. When used as a verb, “Commercialize” or “Commercializing” means to engage in Commercialization. 
 1.13
“Commercialization Plan” has the meaning set forth in Section 6.2.1. 
 1.14 “Commercially Reasonable
Efforts” means: 
 1.14.1 with respect to the obligations of a Party under this Agreement relating to Development or
Commercialization activities, the level of efforts and expenditure of resources required to carry out such obligation in a sustained manner consistent with the efforts and resources such Party typically devotes to a product of similar market
potential, resulting from its own research efforts or development and commercialization collaborations for which it is responsible, at a similar stage in its development or product life, and using commercially reasonable financial resources and
making the respective reasonable investments; or 
 1.14.2 with respect to the obligations of a Party under this Agreement relating to any
other objective, reasonable, good-faith efforts, taking into account industry practices. 
 1.15 “Confidential Information”
means any and all data, materials and information previously, presently or subsequently disclosed by or on behalf of one Party (the “Discloser”) to the other Party (the “Recipient”), including, without limitation,
all financial, business, legal and technical information of Discloser or any of its Affiliates, suppliers, customers and employees (including information about research, development, operations, marketing, transactions, inventions, methods,
processes, materials, algorithms, software, specifications, designs, data, strategies, plans, prospects, Know-How and ideas, whether tangible or intangible), including all copies, abstracts, summaries, analyses and other derivatives of any of the
foregoing. For the avoidance of doubt, “Confidential Information” includes (a) the terms of this Agreement and (b) all information disclosed to a Party by the other Party prior to the Effective Date under the Confidentiality
Agreement. 
 1.16 “Confidentiality Agreement” means that certain confidentiality agreement between DBV and NESTEC made
effective as of January 21, 2015. 

  
 4 

 1.17 “Control” or “Controlled” means, with respect to any
Know-How, Patent Rights or other intellectual property rights, that a Party has the legal authority or right (whether by ownership, license or otherwise) to grant a license, sublicense, access or right to use (as applicable) under such Know-How,
Patent Rights, or other intellectual property rights, including to the other Party on the terms and conditions set forth herein, as applicable, in each case without breaching the terms of any agreement with a Third Party. 

1.18 “Cover” or “Covering” means, with respect to Patent Rights and any product, technology or Know-How,
that such Patent Rights include one or more Valid Claims that would, but for the licenses granted under this Agreement be infringed by Development, Manufacture, use or Commercialization of such product, or the practice of such technology or
Know-How, in the applicable country in which any such activity occurred. 
 1.19 “DBV Improvement” has the meaning set
forth in Section 9.1.3. 
 1.20 “Development” means all activities related to the development of products for the
diagnosis of human diseases and conditions and obtaining Regulatory Approval for such products, including all activities related to research, development, preclinical testing, preclinical toxicology, stability testing, toxicology, formulation, CMC,
Clinical Trials, regulatory affairs, statistical analysis, report writing, Regulatory Filing creation and submission related to obtaining Regulatory Approval for a product, and all other activities directed to obtaining Regulatory Approval. When
used as a verb, “Develop” means to engage in Development. 
 1.21 “Development Milestone” has the meaning
set forth in Section 8.2.1. 
 1.22 “Discloser” has the meaning set forth in Section 1.15. 

1.23 “EHP” means extensively hydrolysed protein. 

1.24 “EMA” means the European Medicines Agency or any successor agency or agencies thereto. 

1.25 “Enforcing Party” has the meaning set forth in Section 9.3.2(b). 

1.26 “EUR” or “€” means Euros. 

1.27 “Executive Officers” means the Chief Executive Officer of DBV and the Chief Executive Officer of Nestlé Health
Science S.A. 
 1.28 “FDA” means the U.S. Food and Drug Administration or any successor agency or agencies thereto. 

1.29 “FDCA” means the United States Food, Drug and Cosmetic Act, as amended (21 U.S.C. §§ 301, et. seq.). 

  
 5 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.30 “Feasibility Milestones” means the Technical Feasibility Milestone and
the Regulatory Feasibility Milestone. 
 1.31 “Feasibility Assessment” means the investigation study for the purpose of
feasibility assessment as described in the Work Plan. 
 1.32 “Field” means diagnosis of CMPA in humans. 

1.33 “Final Determination” means, with respect to the occurrence of any event (including breach of this Agreement), that the
occurrence of such event has been determined to occurred either (a) by mutual written agreement of the Parties or (b) pursuant to the dispute resolution provisions set forth in ARTICLE XVI. 

1.34 “First Commercial Sale” means, with respect to the Licensed Product in a particular country or other jurisdiction, the
first sale of the Licensed Product by NESTEC or any of its Affiliates or Sublicensees for consideration. 
 1.35 “Governmental
Authority” means any nation or government, any state, local or other political subdivision thereof, and any entity, department, commission, bureau, agency, authority, board, court, official or officer, domestic or foreign, exercising
executive, judicial, regulatory or administrative governmental functions. 
 1.36 “ICC” has the meaning set forth in
Section 16.2.2. 
 1.37 “Indemnitee” means, as the context requires, the DBV Indemnitees and/or the NESTEC
Indemnitees. 
 1.38 “Invention” means any and all discoveries, developments, improvements, modifications, formulations,
compositions of matter, processes and other inventions (whether patentable or not patentable) that are invented in the course of activities performed under this Agreement by or on behalf of either Party or both Parties. 

1.39 “JSC” or “Joint Steering Committee” has the meaning set forth in Section 3.1.1. 

1.40 “Key Countries” means [***]. For clarity, this term is only used in this Agreement to describe the effects of
termination in the event of an uncured breach of NESTEC’s obligation to use Commercially Reasonable Efforts to Commercialize the Licensed Product in accordance with Section 15.2.1. 

1.41 “Key [***] Countries” means [***] to be determined by the JSC in accordance with Section 3.1 [***]. 

1.42 “Key Patent Countries” means [***]. 

1.43 “Know-How” means techniques, data, inventions, practices, methods, trade secrets, knowledge, sources of supply, patent
positioning, know-how, skill, experience, test data (including manufacturing, pharmacological, toxicological, preclinical and clinical test data) and analytical and quality control data or descriptions including all proprietary information submitted
to relevant Regulatory Authorities, and in each case in written, oral, electronic or other form. 

  
 6 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.44 “Knowledge” means the actual knowledge of the senior executive officers
of a Party. 
 1.45 “Law” means all laws, statutes, rules, regulations, ordinances, orders, judgments and other
pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign, including all such laws, statutes, rules, regulations, ordinances, orders,
judgments and other pronouncements pertaining to the pharmaceutical industry or the healthcare industry and all anti-bribery or anti-corruption laws, including Anti-Bribery Laws and their implementing regulations and all foreign equivalents thereof.

 1.46 “Licensed Know How” means all Know How Controlled by DBV or any of its Affiliates as of the Effective Date or that
come to be Controlled by DBV or any of its Affiliates at any time during the Term (including any applicable Viaskin® Know How or Joint Know How) that is necessary to Develop or Commercialize
the Licensed Product; however, “Licensed Know How” includes Manufacturing Know How but excludes Know How Controlled by an Acquirer. 

1.47 “Licensed Patents” means all Patent Rights Controlled by DBV or any of its Affiliates as of the Effective Date or that
come to be Controlled by DBV or any of its Affiliates at any time during the Term (including any applicable Viaskin® Patents) that Cover the Licensed Product; however, “Licensed
Patents” excludes Patent Rights Controlled by an Acquirer. Exhibit 1.47 provides an accurate and exhaustive list the Licensed Patents as of the Effective Date. 

1.48 “Licensed Product” means a test for the diagnosis of CMPA that is Developed pursuant to this Agreement and that is
comprised of the following [***]. 
 1.49 “Licensed Technology” means all Licensed Patents and Licensed Know How. 

1.50 “Manufacture” means, with respect to a Product, any and all processes and activities conducted to manufacture
preclinical, clinical and commercial quantities of such, in particular, the production, the manufacture, the processing, the filling, the packaging, the labeling, the inspection, the storage, the warehousing and the shipping of such Product.
Manufacture shall also include the supply of any raw materials or packaging materials with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization, process qualification and validation, commercial
manufacture, stability and release testing, quality assurance and quality control. For clarity, “Manufacturing” has a correlative meaning. 

1.51 “Manufacturing Know-How” means all Know-How Controlled by DBV as of the Effective Date or that comes to be Controlled by
DBV at any time thereafter during the Term, in each case that is necessary to Manufacture the Licensed Product; however, “Manufacturing Know-How” excludes Know-How Controlled by an Acquirer. 

  
 7 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.52 “Manufacturing Transfer Event” means (a) a Supply Failure,
(b) DBV’s (or its contract manufacturers’) insufficient capacity to Manufacture the quantities of Licensed Product reasonably forecasted by NESTEC, (c) the Parties’ joint determination that the supply price offered by DBV
for the Licensed Product is significantly noncompetitive, compared to several quotes of Third Party manufacturer offering at least the same level of quality supply as DBV or (d) a termination of this Agreement by NESTEC in accordance with
Section 15.2.1 (Termination for Material Breach) or in accordance with Section 15.2.3 (Termination for Insolvency). Manufacturing Transfer Event and their handling will be further described in the Supply Agreement, it being
specified that, [***]. 
 1.53 “NESTEC Improvement” has the meaning set forth in Section 9.1.4. 

1.54 “NESTEC Indemnitees” has the meaning set forth in Section 14.1. 

1.55 “NESTEC Know How” means all Know How Controlled by NESTEC or any of its Affiliates as of the Effective Date or that come
to be Controlled by NESTEC or any of its Affiliates at any time during the Term that is necessary to Develop, Manufacture and Commercialize the Licensed Product. 

1.56 “NESTEC Patents” means all Patent Rights Controlled by NESTEC or any of its Affiliates as of the Effective Date or that
come to be Controlled by NESTEC or any of its Affiliates at any time during the Term that Cover the Licensed Product. Exhibit 1.56 provides an accurate and exhaustive list of NESTEC Patents as of the Effective Date. 

1.58 “NESTEC Technology” means NESTEC Patents and NESTEC Know How. 

1.59 “NESTEC Trademark” has the meaning set forth in Section 9.8.1. 

1.60 “Net Sales” has the meaning set forth under Exhibit 1.60. 

1.61 “Patent” means (a) unexpired and currently in force letters patent (or other equivalent legal instrument),
including utility and design patents, and including any extension, substitution, registration, confirmation, reissue, re-examination or renewal thereof, (b) applications for letters patent, a reissue application, a continuation application, a
continuation-in-part application, a divisional application or any equivalent of the foregoing applications, that are pending before a government patent authority and (c) all foreign or international equivalents of any of the foregoing in any
country. 
 1.62 “Patent Challenge” has the meaning set forth in Section 15.2.2. 

1.63 “Patent Rights” means all rights in, to and under Patents. 

  
 8 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.64 “Person” means any individual, firm, corporation, partnership, limited
liability company, trust, business trust, joint venture, Governmental Authority, association or other entity. 
 1.65 “Phase III
Clinical Trial” means a pivotal controlled or uncontrolled human Clinical Trial of a Licensed Product as required to obtain Regulatory Approval for the Licensed Product. 

1.66 “Phase III Clinical Trial Interim Analysis Acceptance” means the earlier of: (i) the notification by NESTEC to DBV
of its go decision after delivery of the Phase III Clinical Trial Interim Analysis Report and (ii) the expiry of a [***] period after delivery of the Phase III Clinical Trial Interim Analysis Report if NESTEC has not terminated this Agreement
pursuant to Section 15.2.5 during such [***] period. 
 1.67 “Phase III Clinical Trial Interim Analysis Report”
means the interim analysis report regarding the Phase III Clinical Trial DBV will prepare and deliver to NESTEC in accordance with the Work Plan. 

1.68 “Phase III Success” means that a Phase III Clinical Trial for the Licensed Product has achieved its primary endpoint in
accordance with its protocol, with [***]. 
 1.69 “Recipient” has the meaning set forth in Section 1.15. 

1.70 “Regulatory Approval” means, with respect to a particular product for the diagnosis of human disease and conditions in a
particular country or regulatory jurisdiction, the registrations, authorizations, clearances and approvals of the applicable Regulatory Authority or other Governmental Authority in such country or regulatory jurisdiction (including, but not limited
to, the FDA, EMA or any notified body) that are necessary to market, sell or otherwise Commercialize such product in such country or regulatory jurisdiction. Regulatory Approval includes Reimbursement Approval only in those countries in the
Territories where Reimbursement Approval is desired prior to making any sales of the applicable product. 
 1.71 “Regulatory
Feasibility Milestone” means [***] determination that the results of the Feasibility Assessment demonstrated positively the feasibility of the project, based on the regulatory strategy criteria as defined in paragraph 4 of the Feasibility
Assessment. 
 1.72 “Regulatory Submission Acceptance” means, with respect to filing for Regulatory Approval after
completion of Phase III Clinical Trials, the first to occur of (a) acceptance by the applicable Regulatory Authority of such filing, or (b) expiration of the thirty (30) day period following the date of submission of such filing
without receipt of notice from the applicable Regulatory Authority within such time period that the filing is not accepted. 

  
 9 

 1.73 “Regulatory Authority” means any national, supra national, regional, state
or local regulatory authority, department, bureau, commission, council or other Governmental Authority (including the FDA, EMA or any notified body) that is responsible for overseeing the Development, use, Manufacture, transport, storage or
Commercialization of the Licensed Product. 
 1.74 “Regulatory Filings” means any application for Regulatory Approval, and
any notification or other submission made to or with a Regulatory Authority that is necessary or reasonably desirable to Develop (including to conduct Clinical Trials), use, Manufacture, transport, store or Commercialize a particular product for the
diagnosis of human diseases and conditions in a particular country or regulatory jurisdiction, whether made before or after receipt of Regulatory Approval in the country or regulatory jurisdiction. The term “Regulatory Filings” shall
include all amendments and supplements to any of the foregoing and all proposed labels, labeling, package inserts, monographs and packaging for a Licensed Product in a particular country. 

1.75 “Reimbursement Approval” means with respect to a particular Licensed Product and a particular country or regulatory
jurisdiction, any pricing and reimbursement approvals of the applicable Regulatory Authority or other Governmental Authority in such country or regulatory jurisdiction that are necessary for a sale or transfer of the Licensed Product to any
applicable Regulatory Authority or other Governmental Authority, or for a sale or transfer of the Licensed Product to be reimbursable or credited by, charged to or otherwise paid for by, in whole or in part, any applicable Regulatory Authority or
other Government Authority in such country or regulatory jurisdiction at the relevant time. 
 1.76 “Relatives” shall mean,
with respect to a Party, its Affiliates or its and their respective employees, directors, representatives, consultants, independent contractors or agents. 

1.77 “Results” has the meaning set forth in Section 12.2. 

1.78 “Royalty Term” has the meaning set forth in Section 8.3.2. 

1.79 “Sales Milestone” has the meaning set forth in Section 8.2.2. 

1.80 “Sales Report” means, with respect to each Calendar Quarter, a report detailing for such Calendar Quarter, on a
country-by-country basis, including but not limited to: (a) gross sales, number of units sold, average price per country, number of samples distributed, and detail of deductions to calculate Net Sales, (b) a calculation of the royalty
payment due on such Net Sales, and (c) the exchange rates and dates used to convert any amounts to Euros, as applicable. 
 1.81
“Scientific Publications” has the meaning set forth in Section 12.2. 
 1.82 “SFDA” means the
State Food and Drug Administration of China. 
 1.83 “Sublicensee” means, with respect to NESTEC, any Third Party to which
NESTEC sublicenses all or any portion of the rights granted to it under Section 7.1. 

  
 10 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.84 “Supply Agreement” means the Manufacturing and Supply Agreement between
DBV and NESTEC contemplated by Section 5.2 pursuant to which DBV will (by itself or through and Affiliate or contract manufacturing organization) supply to NESTEC its requirements of Licensed Product. 

1.85 “Supply Failure” means a Final Determination that DBV has materially failed to meet its obligations to supply Licensed
Product to NESTEC and not cured such failure as will be further defined in the Supply Agreement. 
 1.86 “Target Countries”
means [***]. 
 1.87 “Technical Feasibility Milestone” means [***] determination that the results of the Feasibility
Assessment demonstrated positively the feasibility of the project, based on the criteria defined in paragraphs 1, 2 and 3 of the Feasibility Assessment. 

1.88 “Term” has the meaning set forth in Section 15.1. 

1.89 “Territories” means worldwide. 

1.90 “Third Party” means any Person other than DBV and NESTEC and their respective Affiliates. 

1.91 “Third Party Claim” has the meaning set forth in Section 9.5 

1.92 “Third Party License Agreement” means any agreement (including any settlement agreement) entered into after the
Effective Date with a Third Party, whereby royalties are to be paid to such Third Party based on the grant of rights under Patent Rights Controlled by such Third Party in a country or countries, which Patent Rights are necessary to enable NESTEC to
Commercialize the Licensed Product in a country in the Territory free from infringement of such Patent Rights. 
 1.93
“Trademarks” means all registered and unregistered marks, trade dress rights, logos, taglines, slogans, and other indicia of origin, together with the goodwill associated with any of the foregoing, and all applications,
registrations, extensions and renewals thereof. 
 1.94 “Unified Patent Court” means the Unified Patent Court within the
meaning of the Agreement on a Unified Patent Court of 19 February 2013. 
 1.95 “Unitary Patent Protection” means a
unitary patent protection within the meaning of Regulation (EU) No. 1257/2012 of 17 December 2012 implementing enhanced cooperation in the area of the creation of unitary patent protection. 

1.96 “U.S.” or “US” means the United States of America, its territories and possessions. 

  
 11 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 1.97 “Viaskin® Know
How” means technology and Know-How Controlled by DBV and its Affiliates as of the Effective Date or that come to be Controlled by DBV or any of its Affiliates at any time during the Term related to composition, manufacturing and use of an
adhesive skin patch for delivery of proteins through intact skin consisting of (a) an electrostatic patch, and (b) an electrospray process to spray homogeneous, thin, dry protein layers of electrically charged proteins onto the patch.
“Viaskin® Know How” excludes Know How Controlled by an Acquirer. 
 1.98
“Viaskin® Patents” means all Patents Covering Viaskin® Know How. Exhibit 1.98 provides an accurate and
exhaustive list of the Viaskin® Patents as of the Effective Date. 
 1.99
“Viaskin® Technology” means Viaskin® Patents and Viaskin®
Know How. 
 1.100 “Valid Claim” means a claim of an issued and unexpired patent (as may be extended through supplementary
protection certificate or patent term extension or the like) or a pending claim of an unissued patent application, which has not been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent
jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue,
re-examination or disclaimer or otherwise. 
 1.101 “Work Plan” means the plan setting forth the specific activities to be
undertaken by each of the Parties in connection with the Development of the Licensed Product, and composed of (i) the Feasibility Assessment, (ii) the Study Design Concept and the Work Plan Budget, as may be amended as set forth in this
Agreement. The current version of the Work Plan is attached to this Agreement as Exhibit 1.101. 
 1.102 “Work Plan
Budget” means the budget setting forth the anticipated costs for the Development of the Licensed Product pursuant to the Work Plan, as may be amended as set forth in this Agreement. 

ARTICLE II. 
 DEVELOPMENT

 2.1 Work Plans; Development Obligations. 

2.1.1 The Parties have established the Work Plan which sets forth the specific activities to be undertaken by each of the Parties and their
respective responsibilities in connection with the Development of the Licensed Product, including the following: 
  

	 	•	 	[***]. 

 (collectively, the “Development Activities”) 

  
 12 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 Through the JSC, each Party shall have the right to propose changes to the Work Plan and the Work Plan Budget
on an ongoing basis as necessary. The JSC shall have the authority to review and approve such changes, and upon approval shall agree upon a revised Work Plan incorporating such changes. Notwithstanding the foregoing, the Work Plan shall at all times
contain terms that are consistent with this Section 2.1. If the terms of the Work Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. 

2.1.2 Each Party shall use Commercially Reasonable Efforts to perform its obligations under the Work Plan at its own expense. 

Any costs incurred by DBV in excess of [***] due to (i) reasons outside of DBV’s responsibility as set out in the Work Plan or (ii) related to
demands from any Regulatory Authority or (iii) required by laws, regulations or guidelines applicable to the Licensed Product due to changes in such laws, regulations or guidelines or in their interpretation by Regulatory Authorities, in each
case exceeding the activities contemplated by the Work Plan (the “Excess Development Costs”) shall be allocated [***] to NESTEC and [***] to DBV. 

For the avoidance of doubt, any clinical and operational activities as set out in the Work Plan are within DBV’s responsibility. 

Within thirty (30) days following the end of each Calendar Quarter starting as of the Effective Date, DBV will provide NESTEC and the JSC with
development reports detailing costs incurred by DBV under the Work Plan, including the number of FTE used and the associated FTE rates, in the particular period, to the performance of the activities allocated to DBV under the Work Plan. A list of
the FTE members along with a range of their applicable rates is set forth in Exhibit 2.1.2. DBV will promptly notify NESTEC if it believes it is reasonably likely to incur Excess Development Costs. Notwithstanding the foregoing, if DBV
proposes any change to the Work Plan that is reasonable and will prevent the Parties from incurring Excess Development Costs or will reduce Excess Development Costs, and if NESTEC’s JSC representatives unreasonably refuse to approve such
change, NESTEC will be solely responsible for any resulting Excess Development Costs that are higher than the cost proposed by the amended Work Plan by DBV. 

2.1.3 Audit. Until the full performance of all Development Activities hereunder and for a period of [***] thereafter, DBV shall keep
complete and accurate records pertaining to costs incurred by DBV, its Affiliates and Sublicensees in respect of the Development Activities in sufficient detail to permit NESTEC to confirm the accuracy of the costs detailed in the development
reports provided by DBV to NESTEC and the JSC. 
 In case of Excess Development Costs, NESTEC shall have the right to cause an independent internationally
recognized accounting firm reasonably acceptable to DBV to audit such records for the sole purpose of confirming costs for a period covering not more than the preceding [***]. DBV may require such accounting firm to execute a reasonable
confidentiality agreement with DBV prior to commencing the audit. 
 Such audits may be conducted during normal business hours upon reasonable prior written
notice to DBV, but no more frequently than once per year. 

  
 13 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be made by
the Parties to reflect the results of such audit, which adjustments shall be paid (plus interest calculated under the same method of calculation that Section 8.5) promptly following receipt of an invoice therefor. 

NESTEC shall bear the full cost and expense of such audit unless such audit discloses an overpayment by NESTEC of [***] or more of the amount of Excess
Development Costs due under this Agreement for the audited period, in which case DBV shall bear and reimburse NESTEC for the full cost and expense of such audit. 

2.1.4 DBV makes no representation, warranty or guarantee that the Development activities conducted under the Work Plan will be successful or
that any particular results will be achieved. 
 2.2 Development Licenses. 

2.2.1 Subject to the terms and conditions of this Agreement, NESTEC hereby grants to DBV an exclusive (except vis-à-vis NESTEC),
royalty-free, non-transferable (except in accordance with Section 17.1), non-sublicensable license under the NESTEC Patents and NESTEC Know How during the Term and in the Territories solely to Develop the Licensed Product as set forth in
the Work Plan and to comply with all other obligations of DBV under this Agreement. 
 2.2.2 Subject to the terms and conditions of this
Agreement, DBV hereby grants to NESTEC an exclusive (except vis-à-vis DBV), royalty-free, non-transferable (except in accordance with Section 17.1), non-sublicensable license under the Licensed Patents during the Term and in the
Territories to Develop the Licensed Product as set forth in the Work Plan and to comply with all other obligations of NESTEC under this Agreement. 

2.2.3 Either Party may perform its obligations under the Work Plan through Affiliates and Third Party subcontractors, provided that such Party
shall cause such Affiliates or Third Party subcontractors to comply with such applicable terms and provisions, and shall remain primarily liable for any acts or omissions of such Affiliate or Third Party subcontractors. 

ARTICLE III. 
 GOVERNANCE

 3.1 Joint Steering Committee. 

3.1.1 Establishment; Authority. Within thirty (30) days after the Effective Date, the Parties will establish a joint steering
committee to oversee Development and Commercialization of the Licensed Product (the “JSC”). The JSC’s responsibilities shall include the following: 

(a) reviewing and approving the Work Plan and the Work Plan Budget, and overseeing and evaluating implementation of the Work Plan in
accordance with the Work Plan Budget, including monitoring progress of preclinical and clinical studies of the Licensed Product and otherwise monitoring compliance with the Work Plan; 

  
 14 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) reviewing and approving protocols for clinical trials on Licensed Product conducted
outside of the Work Plan; 
 (c) discussing whether or not the Feasibility Milestones are achieved; 

(d) reviewing, commenting on and approving all Regulatory Filings and other regulatory submissions and all material correspondence with
Regulatory Authorities; 
 (e) reviewing and commenting on Commercialization strategy and the Commercialization Plan; 

(f) determining which are the Key [***] Countries; 

(g) attempting to resolve Disputes arising under this Agreement among the Parties, the Alliance Managers or any project teams of the Parties;
and 
 (h) performing such other tasks and undertaking such other responsibilities as designated to it under this Agreement or the Work
Plan. 
 Notwithstanding anything to the contrary set forth in this Agreement, other than amendments of the Work Plan in accordance with
Section 2.1.1, the JSC shall not have the power to amend or waive compliance with this Agreement, determine any such issue in a manner that would conflict with the express terms and conditions of this Agreement, require any Party to
perform any act that is inconsistent with applicable Law or, without the consent of the affected Party, materially increase or reduce the obligations of the Parties under this Agreement. 

3.1.2 Composition; Voting. 

(a) Within thirty (30) days after the Effective Date, each Party shall appoint three (3) employees to serve on the JSC, each of
which shall have such expertise as is appropriate to the activities of the JSC. Each Party may replace its JSC representatives by written notice to the other Party. 

(b) Each Party shall have one (1) vote on all matters and decisions that are within the responsibility of the JSC, regardless of the
number of such Party’s representatives on the JSC, and any decision or other action by the JSC may only be made by unanimous consensus of the Parties except: 

(i) DBV will have final decision making authority with respect to the [***] matters; 

  
 15 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 (ii) NESTEC will have final decision making authority with respect to [***]; 

(iii) [***], will be mutual consent matters; 

(iv) NESTEC will have final decision making authority with respect to any proposal to enter into a Third Party License Agreement,
provided that the field of such license is limited to CMPA diagnostics and that the entering into a Third Party License Agreement does not materially and adversely impact DBV, would have the effect of diminishing any rights or licenses granted
hereunder or include any admission that the Viaskin® Patents are invalid or unenforceable; 

(v) The members of the JSC will use good faith efforts to reach unanimous consensus on all decisions and other actions that are within
the responsibility of the JSC. 
 3.1.3 Co-Chairpersons. Each Party shall designate one of its JSC representatives to serve as
co-chairperson. The co-chairpersons shall be jointly responsible for calling meetings and shall be jointly responsible for setting the agenda (which shall include a list of all participants expected at a meeting). The co-chairpersons shall alternate
responsibility for circulating such agenda at least fifteen (15) days prior to each meeting and distributing minutes of the meetings pursuant to Section 3.1.5 within fifteen (15) days following such meeting, but will not
otherwise have any greater power (including voting power) or authority than any other member of the JSC. 
 3.1.4 Meetings. The JSC
shall, after appointment of its initial members, meet at least once every Calendar Quarter at times mutually agreed upon by the Parties, and at least two (2) of such meetings each year shall be held in person. The location of the meetings of
the JSC to be held in person shall be agreed upon by the Parties (with the intent that it should alternate between the Parties’ respective headquarters locations or be held at the time and sites of major medical conferences attended by both
Parties). Additionally, either Party may call a special meeting of the JSC upon written notice to the other (and which meeting shall be scheduled promptly at mutually agreeable times) (a) to make any determination under this Agreement that
cannot reasonably be postponed until the next scheduled JSC meeting, (b) for the purpose of resolving disputes in connection with, or for the purpose of reviewing or making a decision pertaining to, any material matter within the purview of the
JSC, the examination or resolution of which cannot reasonably be postponed until the next scheduled JSC meeting or (c) as reasonably necessary to review other matters occurring between JSC meetings. Each such special meeting of the JSC shall be
convened at such time as may be mutually agreed upon by the Parties, but in any event shall be held within fifteen (15) days after delivery of the written notice described in the immediately preceding sentence. Each Party shall use reasonable
efforts to cause its representatives to attend the meetings of the JSC. If a representative of a Party is unable to attend a meeting, such Party may designate an alternate to attend such meeting in place of the absent representative. Each Party
shall bear all the expenses of its representatives on the JSC. Either Party may invite personnel or consultants of the Parties (other than the members of the JSC) having applicable expertise to participate in

  
 16 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 discussions of the JSC from time to time as appropriate to assist in the activities of the JSC with the prior
consent of the other Party, which shall not be unreasonably withheld;, and any such non-member shall be (x) bound by confidentiality and non-use obligations equivalent in scope to those set forth in ARTICLE XII of this Agreement and
(y) under a written obligation to assign to the Party inviting such non-member any inventions of such non-member in the course of or as a result of attending any such meeting. 

3.1.5 Minutes. The minutes of each JSC meeting shall be distributed to the members within fifteen (15) days after the completion
of the relevant meeting and shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by the JSC. Minutes of each JSC meeting shall be approved or
disapproved, and revised as necessary, within thirty (30) days after the applicable JSC meeting and shall be considered Confidential Information of both Parties. 

3.2 Alliance Managers. Promptly after the Effective Date, each Party shall appoint an individual to act as alliance manager for such
Party, which may be one of the representatives of such Party on the JSC (each, an “Alliance Manager”). The Alliance Managers shall be the primary point of contact for the Parties regarding the activities contemplated by this
Agreement and shall facilitate all such activities hereunder and shall be responsible for progressing the alliance activities, otherwise facilitating communication and being the first line of dispute resolution. The Alliance Managers shall attend
all meetings of the JSC and shall be responsible for assisting the JSC in performing its oversight responsibilities. The name and contact information for each Party’s Alliance Manager, as well as any replacement(s) chosen by such Party, in its
sole discretion, from time to time, shall be promptly provided to the other Party in accordance with Section 17.5. Each Party shall provide its Alliance Manager with sufficient resources for the Alliance Manager to perform his or her
role under this Agreement. 
 ARTICLE IV. 

REGULATORY MATTERS 
 4.1
Regulatory Strategy. The JSC shall establish a strategy for seeking Regulatory Approval for the Licensed Product, and the Parties respective responsibilities shall be set forth in the Work Plan. 

4.2 Regulatory Responsibility. 

4.2.1 DBV Regulatory Role. DBV shall be responsible and shall use Commercially Reasonable Efforts to prepare and file, [***], all
Regulatory Filings necessary to obtain Regulatory Approvals in [***], and thereafter to maintain such Regulatory Approvals [***]. 
 Without limiting the
foregoing, DBV shall apply, [***], for Regulatory Approval in the [***]. 

  
 17 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 With NESTEC’s assistance, DBV shall be responsible and shall use Commercially Reasonable Efforts to
prepare and file, [***], all Regulatory Filings necessary to obtain Regulatory Approvals in the following other countries: [***]. Nothing in this Agreement shall oblige DBV to conduct any studies or activities in support of Regulatory Filings with
respect to the Licensed Product other than those set forth in the Work Plan. 
 [***] shall own and be the license holder for all Regulatory Approvals for
the Licensed Product. 
 4.2.2 NESTEC Regulatory Role. 

(a) NESTEC shall use Commercially Reasonable Efforts to prepare and file all Regulatory Filings necessary to obtain, if relevant,
Reimbursement Approvals in the countries where Regulatory Approvals is sought, and thereafter to maintain such Reimbursement Approvals in the name of NESTEC. Without limiting the foregoing, [***]. 

(b) [***], NESTEC shall own and be the license holder for all Reimbursement Approvals for the Licensed Product. 

4.2.3 Regulatory Filing Fees. Notwithstanding anything to the contrary set forth in this Agreement, NESTEC shall be solely responsible
for all filing and maintenance fees and out-of-pocket costs associated with all Regulatory Filings, and shall reimburse DBV for all such fees and costs, as applicable. 

4.3 Cooperation; Effort. Each Party will, at its sole cost and expense, cooperate with the other Party in providing technical
regulatory expertise for assistance in developing the submission strategy for Regulatory Filings and defining technical content and will provide reasonable support to the other Party to ensure timely Regulatory Filings and other regulatory
submissions reasonably necessary to obtain Regulatory Approvals, and any post-Regulatory Approval or Regulatory Filings or other regulatory submissions for the Licensed Product. Each Party shall designate a global regulatory affairs representative
and the other Party shall invite such representative to attend any substantive in-person or other meetings (including telephonic meetings) with Regulatory Authorities. The Parties shall review, comment on and approve all Regulatory Filings and other
regulatory submissions and all material correspondence with Regulatory Authorities through the JSC and in accordance with ARTICLE III of this Agreement. 

ARTICLE V. 

MANUFACTURING AND SUPPLY 

5.1 Development Supply. DBV will use Commercially Reasonable Efforts to Manufacture sufficient quantities of the Licensed Product for
use in Development in accordance with the Work Plan. 
 5.2 Commercialization Supply. 

5.2.1 As soon as reasonably practicable following the Effective Date, the Parties shall negotiate in good faith the terms of the Supply
Agreement, and within [***] following [***], the Parties shall execute such Supply Agreement, which shall contain the terms set forth in Exhibit 5.2.1. 

  
 18 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 5.2.2 Except as otherwise set forth in the Supply Agreement in the event of a Manufacturing
Transfer Event, NESTEC shall exclusively obtain all of NESTEC’s requirements of Licensed Product from DBV and DBV shall supply to NESTEC all of NESTEC’s requirements of Licensed Product for the duration and in accordance with the terms and
conditions of the Supply Agreement. 
 ARTICLE VI. 

COMMERCIALIZATION OF LICENSED PRODUCTS 

6.1 Commercialization Responsibility. Subject to Section 6.2, NESTEC shall be responsible over all Commercialization
activities for the Licensed Product in the Territories at NESTEC’s sole cost and expense. 
 6.2 Commercialization Plans; Oversight;
Diligence. 
 6.2.1 At least [***], NESTEC will deliver to DBV a plan setting forth sufficient details to have a comprehensive overview
of the activities for Commercialization of the Licensed Product throughout the Territories (the “Commercialization Plan”). The Commercialization Plan will be updated by NESTEC at least annually and presented to the JSC. 

6.2.2 [***] will use Commercially Reasonable Efforts to Commercialize the Licensed Product in countries of the Territories where [***] has
obtained Regulatory Approval. Without limiting the foregoing, the Parties agree that [***] Commercially Reasonable Efforts will require [***] to launch the Licensed Product in each Target Country in commercial quantities within [***]. In the event
NESTEC fails to launch the Licensed Product in a Target Country in commercial quantities within [***] following Regulatory Approval as set out above, DBV shall be entitled to terminate the Agreement in such Target Country in accordance with
Section 15.2.1. In the event NESTEC determines that Commercially Reasonable Efforts does not require NESTEC to commence Commercialization activities in any country in the Territories other than the Target Countries, NESTEC shall give DBV
written notice of such determination within a reasonable period of time, but in any event within [***] after any such determination is made, and upon provision of such notice, DBV shall be entitled to terminate this Agreement in such country in
accordance with Section 15.2.1. 
 6.3 Commercialization Reports. Following the receipt of Regulatory Approval for the
Licensed Product in any country in the Territory, NESTEC will be obligated on an annual basis to deliver to DBV through the JSC, in accordance with Section 3.1.1(e), a report describing the status of the Commercialization efforts with
respect to Licensed Product in the Territory, which report shall be sufficient to establish NESTEC’s compliance with Commercialization obligations under this Agreement. 

  
 19 

 ARTICLE VII. 

LICENSES 
 7.1 Grant.

 7.1.1 Patent License. DBV hereby grants to NESTEC an exclusive (including vis-à-vis DBV), royalty-bearing, non-transferable
(except as set forth in Section 17.1), non-sublicensable (except as set forth in Section 7.2) right and license during the Term under the Licensed Patents (a) to Commercialize the Licensed Product in the Field in the
Territories and (b) solely in the event that a Manufacturing Transfer Event occurs, to make and have made the Licensed Product for Commercialization in the Field and in the Territory. 

7.1.2 Know How License. DBV hereby grants to NESTEC an exclusive (including vis-à-vis DBV), royalty-bearing, non-transferable
(except as set forth in Section 17.1), non-sublicensable (except as set forth in Section 7.2) right and license during the Term under the Licensed Know How (a) to Commercialize the Licensed Product in the Field in the
Territory and (b) solely in the event that a Manufacturing Transfer Event occurs, to make and have made the Licensed Product for Commercialization in the Field and in the Territories. In addition, in the event that a Manufacturing Transfer
Event occurs, NESTEC shall have the right to use and disclose the Manufacturing Know-How transferred to it solely as necessary in connection with manufacturing or having Manufactured the Licensed Product; however, any Third Party to whom the
Manufacturing Know-How is transferred shall receive prior approval of DBV, which approval cannot be unreasonably withheld if such Third Party is a reputable contract manufacturing organization, is bound by written obligations not to disclose the
Manufacturing Know-How to any Third Party and to use the Manufacturing Know-How solely for purposes of manufacturing the Licensed Product, and such obligations can reasonably be enforced against the contract manufacturing organization. 

7.1.3 DBV Reservation of Rights. For the avoidance of doubt, DBV and its Affiliates grants no license under, and shall retain all
rights to practice and license, the Licensed Technology outside the scope of the license granted to NESTEC under this Agreement. 
 7.2
Sublicense. Subject to DBV’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed, NESTEC may grant sublicenses of the rights granted to it under Section 7.1.1 and
Section 7.1.2 to one or more Third Parties. If DBV grants such consent, any such sublicense shall be established pursuant to a written agreement that is consistent with the terms and conditions of this Agreement in all material respect
and NESTEC shall remain responsible for all of its obligations under this Agreement notwithstanding any subcontract, and shall be responsible and liable for any act or omission of any Sublicensee that would be a breach of this Agreement by NESTEC.
Any sublicenses granted shall immediately terminate upon termination of this Agreement. 
 7.3 Affiliates. NESTEC may exercise the
rights granted to it under Section 7.1.1 and Section 7.1.2 through its Affiliates, provided that NESTEC shall be responsible and liable for any act or omission of any Affiliate that would be a breach of this Agreement by
NESTEC. 

  
 20 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 7.4 No Other Licenses. Neither Party grants to the other Party any rights, licenses or
covenants in or to any intellectual property, whether by implication, estoppel, or otherwise, other than the license rights that are expressly granted under this Agreement. 

ARTICLE VIII. 
 PAYMENTS

 8.1 Upfront Fee. In consideration of the rights and licenses granted to NESTEC under this Agreement, in addition to the
payments specified in Section 8.2 and Section 8.3, NESTEC shall pay to DBV, on or prior to the date that is sixty (60) days after the Effective Date or, if such date is not a Business Day, on the next Business Day, a one
time, non-refundable, non-creditable fee equal to Ten Million Euros (€10,000,000) (the “Upfront Fee”). DBV may invoice NESTEC for the Upfront Fee on the Effective Date. 

8.2 Milestone Payments. In addition to the payments specified in Section 8.1 and Section 8.3, NESTEC shall,
conditioned upon achievement of the applicable milestone for the Licensed Product, make the following payments to DBV in consideration of the rights and licenses granted to NESTEC under this Agreement: 

8.2.1 Development Milestones. NESTEC shall pay to DBV the following non-creditable, non-refundable payment for the first achievement of
the following milestone events for the Licensed Product (each, a “Development Milestone”): 
  

			
	 Development Milestone Event / Target Date
	  	Payment
	 1. [***]
	  	€[***]
		
	 2. [***]
	  	€[***]
		
	 3. [***]
	  	€[***]
		
	 4. [***]
	  	€[***]
		
	 5. [***]
	  	€[***]
		
	 6. [***]
	  	€[***]
		
	 7. [***]
	  	€[***]
		
	 8. [***]
	  	€[***]
		
	 9. [***]
	  	€[***]
		
	 10. [***]
	  	€[***]
		
	 11. [***]
	  	€[***]
	 TOTAL Amount of Development Milestones Payments:
	  	€[***]

  
 21 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 If any of the milestones set forth in (6) or (7) is achieved whereas any of the milestones set
forth in (3), (4) or (5) has not been achieved, then the milestones set forth in (3), (4) and (5) shall become payable upon achievement of the milestone set forth in (6) or (7). 

Each milestone payment set forth in this Section 8.2.1 shall be payable by NESTEC within [***] after the first achievement of the applicable
Development Milestone for the Licensed Product. If requested by NESTEC, DBV will provide NESTEC with a corresponding invoice for each Development Milestone payment due. 

[***]. 
 8.2.2 Sales Milestones. NESTEC
shall pay to DBV the following non-creditable, non-refundable payments for the first achievement of the amounts set below for aggregate, global Net Sales in a Calendar Year (each, a “Sales Milestone”): 

 

					
	 Aggregate Global Net Sales of Licensed Product

in a Calendar Year
	  	Payment	 
	 [***]
	  	€	[***]	 
	 [***]
	  	€	[***]	 
	 [***]
	  	€	[***]	 

 For purposes of determining achievement of the Sales Milestone, Net Sales of the applicable Licensed Product shall be
aggregated [***]. 
 Each Sales Milestone payment shall be payable only once by NESTEC within [***] after the first achievement of the applicable Sales
Milestone. NESTEC shall provide notice to DBV of such achievement promptly upon achievement of each Sales Milestone. If requested by NESTEC, DBV will provide NESTEC with a corresponding invoice for each Sales Milestone payment due. 

8.3 Royalty Payment; Audits; Payment Reductions. 

8.3.1 Royalty Payments. In addition to the payments specified in Section 8.1 and Section 8.2, in consideration
of the rights and licenses granted to NESTEC under this Agreement, NESTEC shall pay to DBV royalty payments on the applicable portion of cumulative Calendar Year global Net Sales of the Licensed Product at the rates set forth below: 

 

			
	 Cumulative Calendar Year Global Net Sales of the Licensed
Product
	  	Royalty
Rate
	 Portion of cumulative Calendar Year global Net Sales of the Licensed Product [***]
	  	[***]%
	 Portion of cumulative Calendar Year global Net Sales of the Licensed Product [***]
	  	[***]%

  
 22 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 For purposes of determining applicable royalty rates, Net Sales of the Licensed Product shall be aggregated
[***]. 
 8.3.2 Royalty Term. NESTEC’s obligation to pay royalties pursuant to this Section 8.3 shall expire, on a
country-by-country basis, upon the last to occur of: (a) the expiration of the last to expire Valid Claim Covering the Licensed Product or (b) [***] after the First Commercial Sale of the Licensed Product in such country (with respect to
such country, the “Royalty Term”). 
 8.3.3 Payment Reductions. 

(a) Payment Reductions for Third Party Payments. If the JSC approves that NESTEC enters into one or more Third Party License
Agreement(s), then the royalty rates set forth in Section 8.3.1 shall be reduced, on a country-by-country basis, by an amount equal to [***]; however, notwithstanding the foregoing, no royalty payment to DBV shall be reduced pursuant to
this Section 8.3.2(a) to less than [***] of the royalty payment that would otherwise be due to DBV in the absence of a reduction pursuant to this Section 8.3.3(a). 

(b) Payment Reductions pursuant to Section 9.2.1(b). In the event that NESTEC takes over the filing, prosecution, maintenance or
defense of a Licensed Patent pursuant to Section 9.2.1(b), the Parties shall agree in good faith on an appropriate adjustment of the economic terms of this Agreement in order to reduce the sales milestones set forth in
Section 8.2.2 and/or royalty payments set forth in Section 8.3.1. 
 (c) Payment Reductions for
Biosimilar/Generic Product. If a Biosimilar/Generic Product is sold by any Third Party at any time during the Royalty Term in any country in the Territory, the royalty rate payable under Section 8.3.1 on Net Sales in any country in
which the Biosimilar/Generic Product is sold will be reduced by [***]. If this Section 8.3.3(c) applies in a country, then NESTEC shall not be entitled to any reductions under Section 8.3.3(a) in such country. 

(d) Payment Reductions for Infringing Product in the Field. If NESTEC has notified DBV that it wishes to bring an appropriate suit or
other action against such Third Party in accordance with Section 9.3.2(b) on the basis of a Licensed Patent in any country in the Territory and (i) DBV has not elected to enforce such Licensed Patent but (ii), with respect to
infringement of Viaskin® Patents, has notified in writing, under the conditions set forth in Section 9.3.2(b), that it determines in good faith that commencing such suit or action
would have a material and adverse effect on the Viaskin® Patents, so that NESTEC may not commence a suit or take action to enforce such Licensed Patent against such Third Party, the royalty
rate payable under Section 8.3.1 on Net Sales in any country in which the infringing product in the Field is found to be sold or offered for sale will be reduced by [***]. If this Section 8.3.3(d) applies in a country, then
NESTEC shall not be entitled to any reductions under Section 8.3.3(a) in such country. 

  
 23 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 (e) Payment Reduction for Damages following Third Party Claims. [***] of any damages
or other amounts that NESTEC would have to bear following a Third Party Claim and in accordance with Section 9.5, except to the extent comprised in the payments referred to in Section 8.3.3(a), will be deduced from the
payments due globally by NESTEC to DBV under Section 8.2.2 and Section 8.3 for the Calendar Year on which they have been paid by NESTEC, up to a limit of [***] reduction on the payments due by NESTEC on such Calendar Year. In
case of excess, such damages or other amounts shall be deduced from the payments due by NESTEC to DBV under Section 8.2.2 and Section 8.3 for any subsequent Calendar Year, up to a limit of [***] payments reduction per
Calendar Year, until such share of damages or other amounts has been fully deduced. For clarity, in no event shall the aggregate reductions as provided in this Section 8.3.3(e) and in Section 8.3.3(a) reduce the payments to
DBV with respect to a Calendar Year to less than [***] of the amounts that would have been due or royalty rate payable under Section 8.3.1. 

(f) Payment Reduction for DBV’s Uncured Material Breach, Insolvency or under Section 15.2.5(c). In the event NESTEC
terminates for DBV’s Uncured Material Breach, Insolvency or under Section 15.2.5(c) and requests that the license(s) set forth in Section 2.2.2 and ARTICLE VII, and the rights and obligations set forth in ARTICLE IX,
survive termination, in accordance with Section 15.3.2, any Development Milestone not achieved at the date of termination shall not be due, and the payments due to DBV by NESTEC under Section 8.2.2 and Section 8.3
shall be reduced by [***]. 
 8.3.4 Royalty Payment Timing; Royalty Reports. Within forty-five (45) days following the end of
each Calendar Quarter during which royalties accrue, NESTEC shall provide DBV with a Sales Report and any other information reasonably requested by DBV for the purpose of calculating royalties and Sales Milestone payments due under this Agreement.
Any royalty payments due to DBV will be paid on the date of delivery of such Sales Report. In the event that either Party determines that the calculation of Net Sales for a Calendar Quarter deviates from the amounts previously reported to DBV for
any reason (such as, on account of additional amounts collected or Licensed Product returns), NESTEC and DBV shall reasonably cooperate to reconcile any such deviations to the extent necessary under applicable legal or financial reporting
requirements. 
 8.3.5 Audit. Until the expiration of all royalty payment obligations hereunder and for a period of [***] thereafter,
NESTEC shall keep complete and accurate records pertaining to the sale or other disposition of Licensed Products by NESTEC, its Affiliates and Sublicensees in sufficient detail to permit DBV to confirm the accuracy of the royalties and Sales
Milestone payments due hereunder. 
 DBV shall have the right to cause an independent internationally recognized accounting firm reasonably acceptable to
NESTEC to audit such records for the sole purpose of confirming Net Sales and royalties for a period covering not more than the preceding [***]. NESTEC may require such accounting firm to execute a reasonable confidentiality agreement with NESTEC
prior to commencing the audit. 
 Such audits may be conducted during normal business hours upon reasonable prior written notice to NESTEC, but no more
frequently than once per year. 

  
 24 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 Adjustments (including remittances of underpayments or overpayments disclosed by such audit) shall be made by
the Parties to reflect the results of such audit, which adjustments shall be paid (plus interest as set forth in Section 8.5) promptly following receipt of an invoice therefor. 

DBV shall bear the full cost and expense of such audit unless such audit discloses an underpayment by NESTEC of [***] or more of the amount of royalties due
under this Agreement for the audited period, in which case NESTEC shall bear and reimburse DBV for the full cost and expense of such audit. 

8.4 Taxes. All payments under this Agreement shall be made without any deduction or withholding for or on account of any tax, except as
set forth in this Section 8.4. The Parties agree to cooperate with one another and use reasonable efforts to minimize under applicable Law obligations for any and all income or other taxes required by applicable Law to be withheld or
deducted from any of the royalty and other payments made by or on behalf of a Party hereunder (“Withholding Taxes”). NESTEC shall, if required by applicable Law, deduct from any amounts that it is required to pay to DBV hereunder an
amount equal to such Withholding Taxes; provided that the NESTEC shall give DBV written notice prior to paying any such Withholding Taxes. Such Withholding Taxes shall be paid to the proper taxing authority for DBV’s account and, if available,
evidence of such payment shall be secured and sent to DBV within forty-five (45) days after such payment. NESTEC shall, at DBV’s sole cost and expense, as mutually agreed by the Parties, do all such lawful acts and things and sign all such
lawful deeds and documents as the DBV may reasonably request to enable the Parties to avail themselves of any applicable legal provision or any double taxation treaties with the goal of paying the sums due to DBV hereunder without deducting any
Withholding Taxes. In the event that NESTEC restructures payments under this Agreement so that an Affiliate of NESTEC makes payments to DBV under this Agreement, which payments require withholding, and DBV is not able to recover such withheld
amounts, NESTEC agrees to increase the amount payable hereunder by an amount deducted for withholding tax reasons, so that after making all required deductions, DBV receives an amount equal to what it would have received had the payments been made
out of Switzerland. Conversely in the event DBV restructures payments under this Agreement which results in adverse change in Withholding Taxes payable by NESTEC, DBV shall not be entitled to any increased amount payable hereunder. 

8.5 Late Payments. If DBV does not receive payment of any sum due to it under this Agreement on or before the due date, interest shall
thereafter accrue on the sum due to DBV from the due date until the date of payment, such interest to be calculated at a rate equal to the lesser of (a) [***], and (b) the highest rate permitted by applicable Laws. 

8.6 Reporting. All financial reporting hereunder shall be, if applicable, on the basis of international financial reporting standards,
consistently applied. 

  
 25 

 8.7 Currency; Exchange Rate. All payments to be made under this Agreement shall be made in
Euros by bank wire transfer in immediately available funds to a bank account designated by written notice from DBV. With respect to sales not denominated in Euros, NESTEC shall convert each applicable quarterly sales in foreign currency into Euros
by using the then current and reasonable standard exchange rate methodology applied by NESTEC in its worldwide accounting practices, consistent with international financial reporting standards, consistently applied. Based on the resulting sales in
Euros, the then applicable royalties shall be calculated. 
 ARTICLE IX. 

OWNERSHIP OF IP; PROSECUTION AND ENFORCEMENT 

9.1 Ownership. 
 9.1.1
All Patents, Know-How and other intellectual property Controlled by a Party prior to the Effective Date or first invented by a Party outside of the course of activities performed under this Agreement (“Background IP”) shall, as
between the Parties, be deemed owned by the Controlling Party. 
 9.1.2 Subject to Sections 9.1.3 and 9.1.4, (a) any Invention
invented solely by Relatives of a Party or its Affiliates in the course of performing activities under this Agreement, together with all intellectual property rights therein, shall be owned by such Party and (b) any Invention invented jointly
by at least one (1) Relative of each Party or such Party’s Affiliate, together with all intellectual property rights therein (“Joint Inventions”, and all Patents claiming such Joint Inventions, hereinafter, “Joint
Patents”), shall be owned jointly by the Parties, with each joint Party having, unless otherwise set forth in this Agreement, an equal, undivided interest therein, with the unrestricted right to practice, exploit, license and grant its
rights to sublicense any such Joint Invention without a duty of accounting or an obligation to seek consent from the other Party, subject to the rights granted and payment obligations under this Agreement. Each Party shall promptly disclose to the
other Party in writing any Inventions and any written Invention disclosures, or other similar documents, submitted to it by its Relatives describing each and every Invention that constitutes an Invention owned by the other Party or a Joint
Invention, and all Know-How relating to such Invention that is in the disclosing Party’s possession. 
 9.1.3 Notwithstanding
Section 9.1.2, to the extent any Invention comprises (i) an improvement of Viaskin® Technology or other DBV Background IP or (ii) relates to a method of use of the
Licensed Product outside of the Field (a “DBV Improvement”), such DBV Improvement will be solely owned by DBV and shall be deemed Viaskin® Technology or Viaskin® Patents, as applicable. NESTEC agrees to assign and hereby assigns, and procures that any of its Relatives shall assign, all rights, titles and interests in and to all DBV Improvements (and any
intellectual property rights thereto) to DBV and agrees to execute such documents and perform such other acts, and procures that any of its Relatives shall execute such documents and shall perform such other acts, as DBV may reasonably request to
obtain, perfect and enforce its rights to such DBV Improvements and the assignment thereof. 

  
 26 

 9.1.4 Notwithstanding Section 9.1.2, to the extent any Invention comprises an
improvement of any active ingredient provided by NESTEC for use in connection with the Licensed Product or relates to a method of use of the Licensed Product in the Field (a “NESTEC Improvement”), such NESTEC Improvement will be
solely owned by NESTEC. DBV agrees to assign and hereby assigns, and procures that any of its Relatives shall assign, all rights, titles and interests in and to all NESTEC Improvements (and any intellectual property rights thereto) to NESTEC and
agrees to execute such documents and perform such other acts, and procures that any of its Relatives shall execute such documents and shall perform such other acts, as NESTEC may reasonably request to obtain, perfect and enforce its rights to such
DBV Improvements and the assignment thereof. 
 9.2 Prosecution of Patents. 

9.2.1 Patents other than Joint Patents  

(a) DBV shall have sole discretion and authority, at its sole cost and expense, with respect to filing, prosecuting and maintaining all
Licensed Patents (other than Joint Patents) and DBV Improvements, provided that in filing, prosecuting and maintaining any DBV Improvements, DBV shall not disclose any NESTEC’s Confidential Information. DBV shall be obligated on an annual basis
to deliver to NESTEC, through any outside patent attorney designated by NESTEC for that purpose, reasonable information as to the status of the filing, prosecution, maintenance and defense (only, as regards defense, to the extent pertaining to the
Field) of the Licensed Patents in the Key Patent Countries and the contemplated filing, prosecution, maintenance and defense strategy (only, as regards defense, to the extent pertaining to the Field) for the coming year in such Key Patent Countries.
DBV shall notify NESTEC, through the outside patent attorney designated by NESTEC for that purpose, on an ongoing basis any action or event relating to filing, prosecution, maintenance and defense (only, as regards defense, to the extent pertaining
to the Field) of the Licensed Patents in the Key Patent Countries that materially departs from the last report delivered. Notwithstanding the above, DBV shall have final control over such prosecution efforts, provided that DBV shall take into
account any reasonable comments made by NESTEC and provided further that DBV shall use its Commercially Reasonable Efforts to file, prosecute, maintain and defend the Licensed Patents and, in doing so obtain and/or maintain the largest protection
possible for the Licensed Products, in the Key Patent Countries. 
 (b) In the event DBV decides not to file, prosecute, maintain or defend
a Licensed Patent, DBV shall provide NESTEC with at least sixty (60) days advance written notice. In such event, and upon NESTEC’s request, the Parties undertake to discuss in good faith, taking into account any potential materially and
adversely consequences on either Party, DBV’s Patent strategy and the effect on any rights or licensed granted hereunder and on the Commercialization, the possibility for NESTEC to take over the filing, prosecution, maintenance or defense of
such Licensed Patent in DBV’s name. If after good faith discussion, DBV decides to allow NESTEC to take over the filing, prosecution, maintenance or defense of such Licensed Patent, (i) DBV shall execute any document and provide any
assistance required to allow NESTEC to effectively take over the filing, prosecution, maintenance or defense of such Licensed Patent and (ii) the provisions of Section 8.3.3(b) shall apply. 

  
 27 

 (c) NESTEC shall have sole discretion and authority, at its sole cost and expense, with respect
to filing, prosecuting and maintaining all NESTEC Patents (other than Joint Patents) and NESTEC Improvements, provided that in filing, prosecuting and maintaining any NESTEC Improvements, NESTEC shall not disclose any DBV’s Confidential
Information. 
 9.2.2 Joint Patents. The Parties will agree as to their respective responsibilities with respect to the filing,
prosecution and maintaining of Joint Patent applications claiming such Joint Invention, provided that in the absence of agreement, Patent application shall be filed, prosecuted and maintained with the largest protection possible in Target Countries
at shared costs. 
 9.2.3 Cooperation in Prosecution. Each Party shall, at its sole cost and expense, provide the other Party all
reasonable assistance and cooperation in the Patent prosecution efforts described above in this Section 9.2 including providing any necessary powers of attorney and executing any other required documents or instruments for such
prosecution. Such cooperation may further include coordinating filing or prosecution of applications to avoid potential issues during prosecution (including novelty, enablement, estoppel, double-patenting and execution of amendments), and the
assistance of each Party’s relevant personnel. 
 9.3 Enforcement. 

9.3.1 Notification. Each Party shall promptly notify the other Party in writing of any existing or threatened infringement by a Third
Party (i) of the Licensed Patents of which it becomes aware in Field and the Territory and (ii) of the Joint Patents of which it becomes aware in any field of use in any territory, and shall provide to the other Party any and all evidence
and information available to such Party regarding such alleged infringement. 
 9.3.2 Enforcement. 

(a) DBV shall have the sole right but not the obligation, to bring an appropriate suit or other action against any Third Party engaged in
infringement in the Territories based on any Licensed Patents and DBV Improvements. NESTEC shall have the sole right but not the obligation, to bring an appropriate suit or other action against any Third Party engaged in infringement in the
Territory based on NESTEC Patents and NESTEC Improvements 
 (b) Notwithstanding the provision of subclause (a), if NESTEC notifies DBV that
it wishes to bring an appropriate suit or other action against any Third Party engaged in infringement in the Territory in the Field based on Licensed Patents, DBV shall have a period of sixty (60) days after such notification to or by NESTEC
to elect to so enforce such Licensed Patent, as applicable, in the Territory. If DBV does so elect, DBV shall so notify NESTEC in writing during such sixty (60) day period. If DBV does not so elect, NESTEC shall have the right, but not the
obligation, to commence a suit or take action to enforce any such Licensed Patent against such Third Party allegedly perpetrating 

  
 28 

 
such infringement, except, with respect to the Viaskin® Patents, if, during such sixty (60) days period, DBV notifies NESTEC in
writing that it determines in good faith that commencing such suit or action would have a material and adverse effect on the Viaskin® Patents and provides NESTEC, through any outside patent
attorney designated by NESTEC for that purpose, with reasonable evidence in this respect, in which case the provision of Section 8.3.3(d) shall apply. Each Party shall provide to the Party enforcing any such rights under this
Section 9.3.2(b) (the “Enforcing Party”) reasonable assistance in such enforcement, including joining an action as a party plaintiff if so required by applicable Laws to pursue such action, at the Enforcing Party’s
sole expense. The Enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, and shall reasonably consider the other Party’s comments on any such efforts. The Enforcing Party shall bear
and be responsible for all costs incurred in connection with each Party’s activities under this Section 9.3.2(b). The Party not bringing an action with respect to infringement under this Section 9.3.2(b) shall be
entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Party bringing such action. Additionally, the Party not bringing an action under this
Section 9.3.2(b) may have an opportunity to participate in such action, at its sole cost and expense, to the extent that the Parties may mutually agree at the time the Enforcing Party elects to bring such action hereunder. 

(c) Notwithstanding the provision of subclause (a), with respect to Licensed Patents other than Viaskin® Patents or to Joint Patents, any decision with respect to (i) whether or not opting-out from the jurisdiction of the Unified Patent Court, (ii) whether or not withdrawing an opt-out
from the jurisdiction of the Unified Patent Court or (iii) making any action which could have an effect on the possibility to bring a case before the Unified Patent Court or before a national court shall be first discussed by the JSC in
accordance with Article 3.1. 
 (d) Settlement. No Party shall settle any claim, suit or action that it brings under this
Section 9.3.2 involving in any manner that would, in the such Party’s reasonable judgment, materially and adversely impact the other Party or that would have the effect of diminishing any rights or licenses granted hereunder or that
do not include a full and unconditional release from all liability of the other Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. 

(e) If either Party recovers monetary damages from any Third Party in a suit or action described in Section 9.3.2(b) or in a
settlement described in Section 9.3.2 (d), such recovery shall be allocated first to the repayment of costs and expenses of the Party(ies) with respect to the action (on a pro rata basis). Any remaining recovery shall be allocated as
follows: 
  

	 	(i)	if the recovery is based upon NESTEC’s lost profits, then NESTEC shall retain the recovery and pay to DBV the same royalties as set forth in Section 8.3; 

  
 29 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	 	(ii)	if the recovery is based upon the allocation of a reasonable royalty, the Enforcing Party shall retain [***] of such remaining recovery and shall remit [***] of such remaining recovery to the other Party.

 9.4 Patent Oppositions and Other Proceedings. 

9.4.1 By the Parties. Either Party may, at its own costs, bring an opposition, action for declaratory judgment, nullity action,
interference, declaration for non-infringement, reexamination, inter partes review or other attack upon the validity, title, or enforceability of a Patent owned or controlled by a Third Party that would (if valid) Cover the Licensed Product,
provided that (i) such Party shall so notify the other Party and keep the other Party duly informed of the development and status of such action or proceedings, (ii) the Parties shall discuss in good faith the strategy and (iii) the
Parties shall cooperate in good faith in bringing and handling such actions or proceedings. If thereafter a Licensed Patent becomes the subject of any proceeding commenced by any Third Party against which an action or proceeding has been initiated
pursuant to the preceding sentence, then the provisions of Section 9.5 shall apply to the extent the defense of the proceedings, actions or claims referred to in Section 9.5 is concerned. 

9.5 By Third Parties. If a Licensed Patent becomes the subject of any proceeding commenced by a Third Party in the Territory in
connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference, inter partes review or other attack upon the validity, title or enforceability thereof, then DBV shall have the sole right, but not
the obligation, to control such defense at its sole cost and expense, subject, however, to the provisions of Section 9.2.1(a). DBV shall permit NESTEC to participate in the proceedings to the extent permissible under applicable Laws, and
to be represented by its own counsel in such proceedings at NESTEC’s sole cost and expense, provided that (i) NESTEC shall cooperate in good faith with DBV in the proceedings and (ii) DBV retains at all times the sole right to direct
and control such proceedings. 
 9.6 Third Party Claims. In the event of any claim, threat or suit by a Third Party against a Party
that the use of the Licensed Products infringes any Third Party right, including Patents or other intellectual property rights of such Third Party (“Third Party Claim”), said Party shall inform the other Party of such Third Party
Claim, and the Parties shall defend in close cooperation with each other against such Third Party Claim, provided that (i) each Party shall have the final right to control such defense, claim, threat, suit or settlement thereof if such Party is
the sole defendant, and (ii) both Parties shall jointly control such defense, claim, threat or settlement thereof if the Parties are co-defendant and each Party shall bear its own costs incurred, including its internal costs. Notwithstanding
the above, the provisions of Section 9.3.2(b) shall apply mutadis mutandis and, in defending or settling such claim, threat or suit, the Parties shall not make any admission that the Viaskin® Patents are invalid or unenforceable. Subject to Section 8.3.3(a), the damages or other amounts that are awarded to a Third Party as a result of such suit for infringement of Third
Party rights or settlement shall be borne equally by both Parties, whether they are co-defendants or not, irrespective of the Party which has been ordered to pay the damages or other amounts to such Third Party. NESTEC will be responsible to pay

  
 30 

 
to the Third Party any damages or other amounts ordered against it and ordered against both Parties jointly, provided however that in such case the payment reduction provided for in
Section 8.3.3(e) shall apply. DBV will be responsible to pay to the Third Party any damages or other amounts ordered against it, provided however that in such case NESTEC shall promptly reimburse DBV such payments and the payment
reduction provided for in Section 8.3.3(e) shall then apply. 
 9.7 Registration of License. DBV agrees that NESTEC may,
if applicable, register its license under the Licensed Patents (other than the Viaskin® Patents, which will be subject to specific consent from DBV on a case-by-case basis) with the Patent
authorities in the Territories. NESTEC shall, at its expense, prepare and deliver to DBV such instruments and other documents reasonably necessary and in proper form for such registration. The Parties shall mutually agree on the form of documents to
be used for such purpose, and shall cooperate to preserve confidentiality of this Agreement to the extent permitted under applicable Laws in the relevant country. DBV shall execute and return to NESTEC such instruments and documents within thirty
(30) days from the receipt thereof. 
 9.8 Branding and Trademarks. 

9.8.1 Branding. NESTEC shall brand the Licensed Products using a Trademark Controlled by NESTEC (a “NESTEC
Trademark”). 
 9.8.2 NESTEC Trademark. NESTEC shall own all rights in the NESTEC Trademark in the Territory and shall
register and maintain the NESTEC Trademark in the countries and regions in the Territory that it determines reasonably necessary, at NESTEC’s cost and expense. 

9.9 Patent Marking. NESTEC shall use Commercially Reasonable Efforts to mark all Licensed Product in accordance with the applicable
patent marking Law, and shall require all of its Affiliates and Sublicensees to do the same to the extent required by Law. 
 ARTICLE X.

 REPRESENTATIONS AND WARRANTIES 

10.1 The Parties’ Representations and Warranties. Each Party hereby represents and warrants to the other Party that, as of the
Effective Date: 
 10.1.1 Such Party (a) is a corporation or other entity duly organized and subsisting under the applicable Laws of its
jurisdiction of incorporation or organization, and (b) has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be
conducted by this Agreement. 
 10.1.2 Such Party has the power, authority and legal right, and is free to, enter into and perform its
obligations under this Agreement and, in so doing, will not violate or conflict with (a) any other agreement to which such Party is a party as of the Effective Date or (b) any instrument or binding understanding, oral or written, to which
such Party is a party or by which it is otherwise bound. 

  
 31 

 10.1.3 This Agreement has been duly executed and delivered on behalf of such Party and
constitutes a legal, valid, and binding obligation of such Party and is enforceable against it in accordance with its terms. 
 10.1.4 Such
Party has taken all corporate action necessary to authorize the execution and delivery of this Agreement. 
 10.1.5 Except with respect to
Regulatory Approvals for the Licensed Product or as otherwise described in this Agreement, such Party has obtained all necessary consents, approvals, and authorizations of all Regulatory Authorities and other Third Parties required to be obtained by
such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder. 
 10.1.6 None
of such Party, its Affiliates or their respective officers or executive employees, within three (3) years prior to the Effective Date (a) has to such Party’s Knowledge been debarred or is subject to debarment or, convicted of a crime
for which a Person could be debarred before a Regulatory Authority under applicable Laws, or (b) to such Party’s Knowledge, has ever been under indictment for a crime for which a Person could be debarred under such Laws. 

10.1.7 The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict
with or violate any provision of the articles of incorporation, bylaws, limited partnership agreement, or any similar instrument of such Party, as applicable, in any material way, and (b) do not conflict with, violate, or breach or constitute a
default or require any consent under any contractual obligation or court or administrative order by which such Party is bound. 
 10.2
DBV’s Representations and Warranties. DBV hereby represents and warrants to NESTEC that, as of the Effective Date: 
 10.2.1 The
Licensed Technology is Controlled by DBV. Each Licensed Patent owned by DBV has been filed in good faith, has been prosecuted in accordance with any applicable duty of candor and has been maintained in a manner consistent with DBV’s standard
practice, in each case in each applicable jurisdiction in which such Licensed Patent has been filed, and applicable fees (to the extent such fees have come due) have been paid on or before the due date for payment. DBV has taken all reasonable steps
in order to protect the Licensed Know How and, notably, has implemented all confidentiality frameworks and obligations necessary to preserve the secret nature of the Licensed Know How which is not the subject-matter of a Licensed Patent using the
same level of care as it exercises in protecting its other Know-How. 
 10.2.2 Neither DBV nor any of its Affiliates has granted any right
or license, or agreed to grant any right or license, to any Third Party relating to any of the intellectual property rights that are licensed by DBV or any of its Affiliates to NESTEC pursuant to this Agreement that conflict with, or limit the scope
of, any of the rights or licenses granted to NESTEC pursuant to this Agreement. 

  
 32 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 10.2.3 There is no pending claim, suit, action, demand or other proceeding brought or made by
a Third Party against DBV or any of its Affiliates challenging the inventorship, validity or enforceability of any of the Licensed Patents in the Territory, or (b) seeking to subject any of the Licensed Patents to interference, reexamination,
reissue, revocation, opposition, appeal or other administrative proceedings. 
 ARTICLE XI. 

CERTAIN COVENANTS 
 11.1
Covenants. Each Party hereby covenants throughout the Term as set forth below: 
 11.1.1 All of such Party’s and its
Affiliates’ Relatives working under this Agreement will be under the obligation to assign to such Party or such Party’s Affiliate, as applicable, in each case as the sole owner, all right, title and interest in and to their inventions and
discoveries arising in the performance of such work, whether or not patentable, either immediately upon invention or, if applicable Law so provides, upon disclosure to and demand made by such Party or such Party’s Affiliates; provided, however,
that for employees based jurisdiction where a prior obligation to assign is not permitted, the obligation under this paragraph will be deemed satisfied if (a) each such employee is obligated to notify his employer of such inventions and
(b) the employer has an established program for receiving such notifications and timely claiming ownership of or exclusive rights to such inventions after notification. 

11.1.2 Such Party will not, and will cause its Affiliates not to, employ or use any Relative that employs any individual or entity
(a) that has been debarred by a Regulatory Authority under applicable Laws or convicted of a crime for which such Person could be so debarred, or (b) that is the subject of a debarment investigation or proceeding of a Regulatory Authority
under applicable Laws, in each case of clauses (a) and (b), in the conduct of such Party’s or its Affiliates’ activities under this Agreement. If during the Term, a Party has reason to believe that actions or omissions have occurred
that will cause such Party to breach the covenant in the immediately preceding sentence, then such Party promptly shall notify the other Party of same in writing. 

11.1.3 Such Party shall not, and shall cause its Affiliates not to, enter into any agreement or other arrangement with a Third Party that
conflicts with the rights granted to the other Party under this Agreement. 
 11.2 Non-Compete. During the Term, [***]. 

11.3 Insider Dealing and Market Abuse. 

11.3.1 NESTEC acknowledges that DBV is publicly listed on NYSE Euronext market, in Paris, and on Nasdaq market in New York. NESTEC further
acknowledges that (a) it is aware of applicable insider dealing and market abuse laws and regulations and (b) some or all of the Confidential Information may be information which is not public or otherwise generally available and is of a
type such that a person who has that information would be prohibited from using it to deal in securities of DBV under 

  
 33 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 
applicable insider dealing, market abuse or similar law. NESTEC and its Relatives shall not use any of the Confidential Information, while it is not publicly or generally available, to deal, or
to encourage anyone else to deal, in any such securities. NESTEC and its Relatives shall not otherwise use or disclose any Confidential Information in a way that amounts to market abuse or contravenes any applicable insider dealing, market abuse or
similar law. [***]. 
 11.3.2 Conversely DBV acknowledges that NESTEC is a subsidiary of significant importance to Nestlé SA, which
is itself publicly listed on the SIX Swiss Exchange “Swiss Blue Chip Segment”, and therefore hereby agrees that Section 11.3.1 shall apply mutatis mutandis to DBV in respect of Nestlé SA and NESTEC. 

ARTICLE XII. 

CONFIDENTIALITY ; SCIENTIFIC PUBLICATIONS 

12.1 Confidentiality Obligations. 

12.1.1 Subject to Section 12.2, during the Term and for a period of five (5) years thereafter, or ten (10) years after
the Effective Date, whichever is longer, Recipient: 
 (a) shall hold in strict confidence any and all Confidential Information disclosed to
it by Discloser and shall not use, nor disclose or supply to any Third Party, nor permit any Third Party, to have access to Discloser’s Confidential Information, without first obtaining the written consent of Discloser, other than
Recipient’s employees and agents who have a need to know in connection with the performance of its obligations and exercise of its rights under this Agreement that are apprised of the confidential nature of the Confidential Information and are
bound by obligations with respect to such Confidential Information substantially similar to those set forth in this Agreement; 
 (b) shall
take all reasonable precautions necessary or prudent to prevent material in its possession or control that contains or refers to Discloser’s Confidential Information from being destroyed or lost, or discovered, received, used, intercepted or
copied by any Third Party; and 
 (c) may disclose Discloser’s Confidential Information only to its Relatives, Affiliates, actual and
potential Sublicensees, actual and potential collaborators, and actual and potential investors or acquirers, in each case solely to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, the performance of
Recipient’s obligations and exercise of Recipient’s rights under this Agreement, and may disclose Discloser’s Confidential Information contained in reports provided by Discloser pursuant to this Agreement to Recipient’s actual
and potential investors or acquirers; provided in each case that such Relatives, Affiliates, actual and potential Sublicensees, actual and potential collaborators and actual and potential investors or acquirers are bound by terms and conditions of
confidentiality no less protective than the terms and conditions that bind Recipient hereunder; provided, however, that the duration of such terms and conditions of confidentiality for such recipients shall be no less than five (5) years. 

  
 34 

 For the avoidance of doubt, it is understood that Recipient shall be liable for any breach of the confidentiality
obligation under this Section 12.1 by any Person to whom Recipient discloses or otherwise provides access to the Discloser’s Confidential Information. 

12.1.2 The obligations of confidentiality and non-use under this Section 12.1 shall not apply to, and Recipient shall have no
further obligations under this Section 12.1 with respect to, any of Discloser Confidential Information, to the extent that Recipient can demonstrate that such Discloser Confidential Information: 

(a) is or becomes part of the public domain without breach by Recipient of this Agreement; 

(b) was rightfully in Recipient’s possession before disclosure by Discloser to Recipient and was not acquired directly or indirectly
from Discloser, as documented by Recipient’s written records; 
 (c) is obtained from a Third Party with no applicable obligation of
confidentiality to Discloser, and such Third Party has a right to disclose such Confidential Information to Recipient; 
 (d) is developed
independently by Recipient without use of or reference to Discloser’s Confidential Information, as evidenced by Recipient’s written records; or 

(e) is required to be revealed in response to a court decision or administrative order, or to otherwise comply with applicable Law,
applicable rules of any recognized stock exchange or quotation system or applicable rules or requirements of the Securities and Exchange Commission or other Governmental Authority or Regulatory Authority, provided, that in each such case Recipient
shall inform Discloser immediately by written notice and cooperate with Discloser using its Commercially Reasonable Efforts either to seek protective measures for such Discloser Confidential Information, or to seek confidential treatment of such
Discloser Confidential Information, and in any case Recipient shall disclose only such portion of the Discloser Confidential Information which is so required to be disclosed. 

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or
available to the general public or in the rightful possession of Recipient unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of Recipient. 

12.1.3 Nothing herein shall prevent Recipient from disclosing any Discloser Confidential Information to the extent that such Discloser
Confidential Information is required to be used or disclosed for the purposes of seeking or obtaining approvals for the Licensed Products from Regulatory Authorities, including Regulatory Approvals, or seeking or maintaining patent protection for
Inventions it owns or has responsibility for prosecuting under ARTICLE IX. 

  
 35 

 12.2 Scientific Publication. The Parties acknowledge that each Party may have a legitimate
interest in publishing in a journal, paper, magazine, present at professional meetings or make similar disclosures of information specifically related to the Licensed Product in the Field (“Results”) (“Scientific
Publications”). Such Scientific Publications shall comply with widely accepted scientific standards. 
 Any draft Scientific
Publication intended to be submitted for publication or other disclosure by one of the Parties hereto shall first be sent to the other Party, at least ninety (90) calendar days in advance of the submission for publication or other disclosure,
in order to allow such Parties to review the publication or other disclosure. The other Parties shall have the right to object in order to preserve: (i) its intellectual property by delaying such publication, e.g., because the publication
contains Results that are patentable or require protection under Article 21 of Regulation (EC) No. 1924/2006), (ii) its Confidential Information and/or (iii) its general communication strategy. In the event that a Party makes such an
objection, the Parties shall negotiate an acceptable version and timing for the publication. The Party responsible for the Scientific Publication shall (i) refrain from making such presentation or publication until the Parties have filed patent
application(s) directed to the patentable Results, or otherwise ensured protection for the Results (e.g. by making an application under Article 13.5 or 14 of Regulation (EC) No. 1924/2006) contained in the proposed presentation or publication;
the other Parties shall use Commercially Reasonable Efforts to file said patent application(s) or seek such protection within a period of sixty (60) calendar days from the date of the objection; and (ii) remove any Confidential Information
of the other Parties from the proposed presentation or publication. 
 Each Party’s contribution shall be acknowledged in any
publication by co-authorship or acknowledgment, whichever is appropriate in accordance with customary scientific practice. In case of joint publications, the citation order and respective functions of the authors (e.g. first author, last author,
corresponding author) shall be determined in good faith by the Parties, in accordance with the rules applicable in the scientific community. Once approval has been granted for a particular disclosure, such disclosed information may be subsequently
disclosed without requiring additional approval for each instance of disclosure. 
 For clarification, the aforementioned clauses do not
restrict the obligations of the Parties according to applicable Law to publish or otherwise disclose results of Clinical Trials. 

  
 36 

 ARTICLE XIII. 

PRESS RELEASES ; PUBLICITY 

13.1 Publicity. Except as otherwise permitted under this Agreement, no disclosure shall be made by either Party concerning the
execution of this Agreement or the terms and conditions hereof without the prior written consent of the other Party, which shall not be unreasonably withheld, conditioned or delayed. 

13.2 Press Release. Notwithstanding the foregoing in Section 13.1, each Party may issue a press release following the
execution of the Agreement, subject to the prior written consent of the other Party, which consent shall not be unreasonably withheld, delayed or conditioned. If any such press release is required by law, including required by the Securities and
Exchange Commission and any other Governmental Authority or Regulatory Authority, then the provisions of Section 13.4 shall apply. 

13.3 Disclosure of Agreement to Third Parties. Notwithstanding the foregoing in Section 13.1, either Party may disclose to
bona fide potential investors, lenders, acquirers, acquirees, and collaborators, and to such Party’s consultants and advisors, the existence and terms of this Agreement to the extent necessary in connection with a proposed equity or debt
financing of such Party, or a proposed acquisition or business combination, so long as such recipients are bound in writing to maintain the confidentiality of such information in accordance with the terms of this Agreement and not use such
information for any purpose other than the evaluation of the applicable financing or acquisition. 
 13.4 Disclosures Required by
Law. Each Party agrees that it shall cooperate fully and in a timely manner with the other Party with respect to all disclosures required by the Securities and Exchange Commission and any other Governmental Authority or Regulatory Authority,
including requests for confidential treatment of Confidential Information of either Party included in any such disclosure. Notwithstanding any other provision of this Agreement, either Party may issue any public announcement or other disclosure that
it is advised by legal counsel is required under applicable Laws or the applicable rules of any recognized stock exchange or quotation system, provided that the Parties shall coordinate with each other with respect to the timing, form and content of
such required disclosure to the extent practicable under the circumstances, and the Party seeking such disclosure shall use Commercially Reasonable Efforts to provide the other Party with reasonable advance notice thereof (including a copy of the
proposed disclosure) and, in any event, at least three (3) days’ advance notice. Any request for revision to the content of said disclosure by the non-disclosing Party shall be furnished to the disclosing Party as promptly as necessary for
the disclosing Party to comply with such requirements in a timely manner. Without limiting the foregoing, each Party shall consult in good faith with the other Party on the provisions of this Agreement (for the avoidance of doubt, including the
schedules and exhibits hereto) to be redacted in any filings made by either Party with the Securities and Exchange Commission or as otherwise required by applicable Law. 

13.5 Right to Further Disclose. Once a public disclosure that is required pursuant to applicable Law, pursuant to applicable rules of
any recognized stock exchange or quotation system or by the Securities and Exchange Commission or other Governmental Authority or Regulatory Authority, is made, in each case in accordance with this Section 13, the content of such
disclosure (or any portion thereof) may be repeated in one or more subsequent disclosures without any obligation of the disclosing Party to give any notices or obtain any consents for such disclosure that would otherwise be required under this
Section 13. 

  
 37 

 ARTICLE XIV. 

LIABILITY - INDEMNIFICATION 

14.1 Indemnification by DBV. 

14.1.1 DBV shall defend, indemnify and hold harmless NESTEC and its employees, officers and directors (collectively, the “NESTEC
Indemnitees”) from and against any and all liabilities, losses, costs, damages and expenses, including reasonable attorneys’ fees (collectively, “Damages”), to the extent arising out of or resulting from any claim,
suit, action, demand or other proceeding (collectively, “Claims”) made or brought against one or more NESTEC Indemnitees by a Third Party in connection with (a) the gross negligence, recklessness, or intentional wrongful acts or
omissions of DBV , in connection with the performance by or on behalf of DBV of DBV’s obligations or exercise of DBV’s rights under this Agreement, and (b) any material breach by DBV of any representation, warranty or covenant of DBV
set forth in this Agreement; except, in any such case, to the extent such Damages are reasonably primarily attributable to any circumstances indemnifiable pursuant to Section 14.2. 

14.1.2 In addition, without prejudice to Section 15.2.1, DBV hereby agrees to indemnify, defend, and hold harmless NESTEC
Indemnitees from and against any material breach by DBV or its Affiliates to comply with its/their respective applicable obligations under this Agreement. 

14.2 Indemnification by NESTEC. 

14.2.1 NESTEC shall defend, indemnify and hold harmless DBV and each of its employees, officers and directors (collectively, the “DBV
Indemnitees”) from and against any and all Damages, to the extent arising out of or resulting from any Claim made or brought against one or more DBV Indemnitees by a Third Party in connection with (a) the gross negligence,
recklessness, or intentional wrongful acts or omissions of NESTEC, in connection with the performance by or on behalf of NESTEC of NESTEC’s obligations or exercise of NESTEC’s rights under this Agreement, (b) any material breach by
NESTEC of any representation, warranty or covenant of NESTEC set forth in this Agreement, and (c) Commercialization of the Licensed Product by or on behalf of NESTEC, its Affiliates or Sublicensee; except, in any such case, to the extent such
Damages are reasonably primarily attributable to any circumstances indemnifiable pursuant to Section 14.1. 
 14.2.2 In
addition, without prejudice to Section 15.2.1, NESTEC hereby agrees to indemnify, defend, and hold harmless DBV Indemnitees from and against any material breach by NESTEC or its Affiliates to comply with its/their respective applicable
obligations under this Agreement. 
 14.3 Indemnification Procedure. 

14.3.1 Each Party shall notify the other in the event it becomes aware of a Third Party Claim for which indemnification may be sought pursuant
to this ARTICLE XIV. 

  
 38 

 In case any Claim (including any governmental investigation) shall be instituted involving any Party or its
Indemnitees in respect of which indemnity may be sought pursuant to this ARTICLE XIV, such Party (the “Indemnified Party”) shall promptly notify the other Party (the “Indemnifying Party”) in writing (an
“Indemnification Claim Notice”); provided, that the failure to promptly provide an Indemnification Claim Notice shall not relieve the Indemnifying Party of its indemnification obligations except, and only to the extent, that the
Indemnifying Party is actually incrementally damaged as a result of such failure. 
 The Indemnifying Party and Indemnified Party shall promptly meet to
discuss how to respond to any claims that are the subject matter of such proceeding. 
 At its option, the Indemnifying Party may assume the defense of a
Third Party Claim subject to indemnification as provided for in this Section 14.3 with competent counsel free of any conflict of interest with the Indemnified Party by giving written notice (a “Defense Election Notice”)
to the Indemnified Party within thirty (30) days after its receipt of the applicable Indemnification Claim Notice (the “Election Time Period”), solely for claims (a) that solely seek monetary damages and (b) as to
which the Indemnifying Party expressly agrees in writing that, as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge the claim in full (the matters described in
(a) and (b), the “Litigation Conditions”). If the Indemnifying Party does not deliver a Defense Election Notice to the Indemnified Party during the applicable Election Time Period, or if any Litigation Condition is not
satisfied, the Indemnified Party will assume responsibility for and control such defense and, without limiting the Indemnifying Party’s indemnification obligations, the Indemnifying Party will reimburse the Indemnified Party for all costs and
expenses, including reasonable attorneys’ fees, incurred by the Indemnified Party in defending itself. 
 14.3.2 Upon assuming the
defense of a Third Party Claim in accordance with this Section 14.3, the Indemnifying Party shall be entitled to appoint competent counsel free of any conflict of interest with the Indemnified Party in the defense of the Third Party
Claim. Should the Indemnifying Party assume and continue the defense of a Third Party Claim, except as otherwise set forth in this Section 14.3, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses
subsequently incurred by such Indemnified Party after the date of assumption of defense in connection with the analysis, defense, countersuit or settlement of the Third Party Claim. Without limiting this Section 14.3, any Indemnified
Party will be entitled to participate in, but not control, the defense of a Third Party Claim for which it has sought indemnification hereunder and to engage counsel of its choice for such purpose; provided, however, that such engagement will
be at the Indemnified Party’s own cost and expense unless (a) the engagement thereof has been specifically requested by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume and actively further the
defense and engage counsel in accordance with this Section 14.3 (in which case the Indemnified Party will control the defense), or (c) the Indemnifying Party no longer satisfies the Litigation Conditions. 

  
 39 

 14.3.3 Subject to the Litigation Conditions continuing to be satisfied, the Indemnifying Party
will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Damages, on such terms as the Indemnifying Party, in its reasonable discretion, will deem appropriate (provided, however, that
such terms (a) shall include a complete and unconditional release of the Indemnified Party from all liability with respect thereto and (b) shall not include any admission of fault by, or impose any liability or obligation on, the
Indemnified Party), and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay pursuant to such settlement or disposal of such claim prior to the time such payments become due by the Indemnified Party.
With respect to all other entries of judgment, entries into settlements or other dispositions of Damages in connection with a Third Party claim for which the Indemnifying Party has assumed the defense in accordance with this
Section 14.3, the Indemnifying Party will only have authority to consent to the entry of such judgment, entry into such settlement or such other disposition of Damages if it has obtained the Indemnified Party’s prior written
consent, not to be unreasonably withheld, conditioned or delayed. 
 14.3.4 The Indemnifying Party that has assumed the defense of the Third
Party Claim in accordance with this Section 14.3 (and continues to maintain control of such defense pursuant to this Section 14.3) will not be liable for any settlement or other disposition of any Damages by an Indemnified
Party that is reached without the prior written consent of such Indemnifying Party. The Indemnified Party will not admit any liability with respect to, or settle, compromise or discharge, any Third Party claim without first offering to the
Indemnifying Party the opportunity to assume the defense of the Third Party Claim in accordance with this Section 14.3. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will cooperate
in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses including to the extent possible, former employees and attend such conferences, discovery proceedings, hearings, trials and
appeals as may be reasonably requested in connection with such Third Party Claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records
and information that are reasonably relevant to such Third Party claim, and making Relatives available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. The Indemnifying Party will
reimburse the Indemnified Party for all its reasonable out of pocket expenses incurred in connection with such cooperation. 
 14.4
Insurance 
 Each Party shall maintain, at its cost, a program of insurance or self-insurance against liability and other risks associated with its
activities and obligations under this Agreement, including its Clinical Trials, its Development, use, Manufacture and Commercialization of the Licensed Product and its indemnification obligations hereunder, in such amounts, subject to such
deductibles and on such terms as are customary for the activities to be conducted by it under this Agreement. All insurance required by this Section 14.4 shall be maintained during the Term and each Party shall, from time to time,
provide copies of certificates of such insurance to the other Party upon request. Further, each Party shall list the other Party as an additional insured on general liability policy with respect to legal liability arising towards Third Parties out
of operations performed by the other Party in 

  
 40 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 
connection with this Agreement but only to the extent of property damage and bodily injury caused directly and exclusively by the sole fault or negligence of the other Party. All insurance
required by this Section 14.4 shall be maintained for at least three (3) years following expiration or termination of this Agreement. 

14.5 Limitation of Liability; Exclusion of Damages; Disclaimer. 

14.5.1 EXCEPT TO THE EXTENT A PARTY IS REQUIRED TO PROVIDE INDEMNIFICATION UNDER SECTION 14.1 OR SECTION 14.2, AND EXCEPT IN THE
CASE OF A BREACH OF ARTICLE XII, AND WITHOUT LIMITING THE LIABILITY OF A PARTY FOR INFRINGEMENT OR MISAPPROPRIATION OF THE INTELLECTUAL PROPERTY RIGHTS OF THE OTHER PARTY OR ANY OF ITS AFFILIATES OR FOR FRAUD OR WILLFUL MISCONDUCT, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS, DIMINUTION OF VALUE, OR OTHER ECONOMIC
LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON PERFORMANCE HEREUNDER. 
 14.5.2 EXCEPT AS
EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDES ANY REPRESENTATIONS OR WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED, REGARDING ANY SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL OTHER REPRESENTATIONS AND
WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS AND IMPLIED, INCLUDING REGARDING TITLE, VALIDITY, PATENTABILITY, ENFORCEABILITY OF PATENT RIGHTS, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND FREEDOM FROM INFRINGEMENT
OF THIRD PARTY RIGHTS, AND ANY WARRANTIES ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. 
 ARTICLE XV. 

TERM; TERMINATION 
 15.1
Term. This Agreement shall become effective as of the Effective Date and shall remain in effect, on a country-by-country basis, until the last to occur of (a) [***] from the First Commercial Sale of the Licensed Product in such country,
(b) the expiration of the last-the-expire Valid Claim under the Licensed Patents in such country, or (c) the date upon which sales of a Biosimilar/Generic Product constitutes more than [***] of the domestic sales for diagnostic tests for
CMPA market in such country in the Territories; in each case of (a), (b) and (c), unless this Agreement is earlier terminated as set forth below (the “Term”). 

  
 41 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 In the event of expiration of this Agreement in a particular country pursuant to this
Section 15.1, upon the date of such expiration DBV hereby grants NESTEC a non-exclusive, royalty-free, perpetual, fully paid-up license under the Licensed Patents to (x) Commercialize the Licensed Products in the Field in such
country, and (y) if a Manufacturing Transfer Event has previously occurred, to make and have made the License Product for Commercialization in such country. In such case, to the extent permitted by law, DBV shall provide all reasonable
assistance, within the limit of [***] following expiration, required by NESTEC in order to make any Regulatory Filings that are necessary to continue to Commercialize the Licensed Product. 

15.2 Early Termination. 

15.2.1 By Either Party for Material Breach. Without prejudice and in addition to any other contractual remedy the non-breaching Party
may have with respect to this Agreement, either Party may terminate this Agreement by providing ninety (90) days’ prior written notice (or thirty (30) days’ prior written notice in the event such material breach is solely based
on the breaching Party’s failure to pay any amounts due hereunder) upon a material breach of this Agreement by the other Party, which termination will take effect automatically at the end of such ninety (90) or thirty (30) day period
(or, if applicable, the extended cure period set forth below) if the breach is not cured as set forth below. 
 The notice of termination shall specify the
nature of the material breach and the breaching Party shall have the opportunity to cure such breach within the period set forth above. 
 The Parties agree
that: 
 (a) in the event of an uncured breach of NESTEC’s obligation to use Commercially Reasonable Efforts to Commercialize the
Licensed Product, under the conditions set forth under Section 6.2.2, in any country in the Territory, DBV shall be entitled to terminate this Agreement pursuant to this Section 15.2.1 but solely on a country-by-country
basis; 
 (b) in the event of an uncured breach of NESTEC’s obligation to (i) launch the Licensed Product in commercial quantities
[***] as set forth under Section 6.2.2 or (ii), following expiration of such [***] period, use Commercially Reasonable Efforts to Commercialize the Licensed Product under the conditions set forth under Section 6.2.2, in each
case in all the Key Countries, DBV shall be entitled to terminate this Agreement pursuant to this Section 15.2.1, in its entirety. For the sake of clarity, in the event of an uncured breach of NESTEC’s obligations mentioned in
(i) or (ii) above in one or more but not all Key Countries, DBV shall only be entitled to terminate this Agreement on a country-by-country basis, as set forth in subclause (a) above. 

15.2.2 By DBV for Patent Challenge. Except to the extent prohibited pursuant to the laws of a country in which a Licensed Patent is
pending, DBV shall have the right to terminate this Agreement in its entirety immediately upon written notice to NESTEC if NESTEC or any of its Affiliates or Sublicenses, directly or through assistance granted to a Third Party, commences or
participates in any administrative, judicial or similar proceeding challenging the validity, enforceability and/or patentability of any Licensed Patent (such action, a “Patent Challenge”). 

  
 42 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 15.2.3 By Either Party for Insolvency. Either Party (the “Non-Debtor
Party”) may terminate this Agreement in its entirety effective immediately upon delivery of written notice to the other Party (the “Debtor Party”) if the Debtor Party is dissolved or liquidated, files or has filed against
it a petition as a debtor under applicable Bankruptcy Laws that is not dismissed within sixty (60) days, makes an assignment of all or substantially all of its property for the benefit of its creditors or has a receiver or trustee appointed for
all or substantially all of its property. 
 15.2.4 For Force Majeure. This Agreement may be terminated in its entirety as set forth
in Section 17.14.2. 
 15.2.5 Specific Termination Cases. 

(a) NESTEC may terminate this Agreement by providing at least [***] days’ prior written notice to DBV if the Technical Feasibility
Milestone is not achieved on or prior to [***]. 
 (b) NESTEC may terminate this Agreement by providing at least [***] days’ prior
written notice to DBV if the Regulatory Feasibility Milestone is not achieved on or prior to [***]. 
 (c) NESTEC may terminate this
Agreement in case of a Third Party becomes the Acquirer of DBV by providing at least [***] days’ prior written notice to DBV. 
 15.2.6
By NESTEC for Convenience. NESTEC may terminate this Agreement by providing at least [***] days’ prior written notice to DBV: 
 (i) in
case of Phase III Delay (as defined below) considering that, once [***], NESTEC will have no right to discontinue the Development activities and accordingly to terminate this Agreement prior to the completion of the first pivotal Phase III Clinical
Trial for the Licensed Product in the US; 
 and/or 

(ii) [***] after completion of the first pivotal Phase III Clinical Trial for the Licensed Product; 

and/or 
 (iii) within a [***] period after
delivery of the Phase III Clinical Trial Interim Analysis Report. 
 For the purposes of the foregoing, “Phase III Delay” shall mean a
delay by [***]. 

  
 43 

 15.3 Effects of Termination. 

15.3.1 Effect of Termination by DBV for NESTEC’s Uncured Material Breach, Patent Challenge or Insolvency. If DBV elects to
terminate the Agreement in accordance with Section 15.2.1 (Termination for Material Breach), or in the event of termination by DBV in accordance with Section 15.2.2 (Termination for Patent Challenge) or by DBV in accordance
with Section 15.2.3 (Termination for Insolvency), in each case without prejudice and in addition to any contractual remedy either Party may have with respect to this Agreement, or if NESTEC terminates for convenience pursuant to
Section 15.2.6, the following shall apply: 
 (a) NESTEC agrees to grant and hereby grants to DBV and its Affiliates, effective
upon such termination, an exclusive, non-transferrable, royalty-free, fully paid up, perpetual, irrevocable license (with the right to grant sublicenses through multiple tiers) under the NESTEC Technology (including any Joint Patents) to make, have
made, use, sell, offer for sale in import the Licensed Product worldwide (except in the event the termination relates only to a particular country, in which case the rights will apply to the terminated countries only). For the avoidance of doubt,
NESTEC shall retain all rights to practice and license the NESTEC Technology outside the scope of the license granted to DBV under this subclause 15.3.1(a). 

(b) Upon DBV’s request, NESTEC shall transfer to DBV any and all regulatory data and Know-How, Regulatory Approvals and Reimbursement
Approvals relating to the Licensed Product in the applicable country(ies). 
 (c) NESTEC shall negotiate in good faith with DBV a license
for transitional use of any NESTEC Trademark that has been used in commerce with the Licensed Product (excluding any corporate name or logo of NESTEC or any of its Affiliates and any trademarks that are used by NESTEC or any of its Affiliates on
products that are not the Licensed Product), together with all goodwill relevant thereto, throughout the Territory, provided royalty-free, fully paid up. 

(d) provide any other assistance as reasonably requested by DBV in connection with the further Development and Commercialization of the
Licensed Product in the terminated country(ies). 
 15.3.2 Effect of Termination by NESTEC for DBV’s Uncured Material Breach,
Insolvency or under Section 15.2.5(c). If NESTEC elects to terminate the Agreement in accordance with Section 15.2.1 (Termination for Material Breach), or in the event of termination by NESTEC in accordance with
Section 15.2.3 (Termination for Insolvency) or in the event NESTEC decides to terminate the Agreement in accordance with Section 15.2.5(c), this shall be without prejudice and in addition to any contractual remedy NESTEC may
have with respect to this Agreement. However, NESTEC shall have the option of requesting that the license(s) set forth in Section 2.2.2 and ARTICLE VII and the rights and obligations set forth in ARTICLE IX, survive termination, in which
case (i) NESTEC shall make payments in accordance with Section 8.3.3(f), and (ii) shall not be admissible to seek any other contractual remedy it may have with respect to this Agreement. 

  
 44 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 In any case, the following shall apply: 

(a) DBV will provide NESTEC with reasonable cooperation to transition to NESTEC the management and continued performance of any activities
under the Work Plan (including clinical or other studies in progress) then being conducted by DBV or its Affiliates related to the Licensed Product which NESTEC determines (in compliance with applicable Laws and ethical guidelines) to continue. 

(b) DBV will provide all reasonable assistance, within the limit of [***] following termination, required by NESTEC in order to make any
Regulatory Filings that are necessary to continue to Commercialize the Licensed Product and will use Commercially Reasonable Efforts to transfer to NESTEC any and all regulatory data and Know-How, and all other filings and submissions with and to
Regulatory Authorities with respect to the Licensed Product. 
 (c) only in the event NESTEC elects to terminate the Agreement in accordance
with Section 15.2.1 (Termination for Material Breach) or Section 15.2.3 (Termination for Insolvency), NESTEC may (at its option) request (i) that DBV transfer the Manufacturing Know How to NESTEC in accordance with the
Supply agreement and (ii) that the provisions of Section 5.2.2 apply and NESTEC shall have the right to terminate the Supply agreement and/or to Manufacture and/or have Manufactured the Licensed Product by any Third Party and DBV
shall provide all reasonable assistance, within the limit of [***] following termination, requested by NESTEC that are necessary to continue to Manufacture and/or have Manufactured the Licensed Product; provided that NESTEC shall use its
Commercially Reasonable Efforts to retain the CMO(s) registered in the Regulatory Approvals for the Manufacture of the Licensed Products. 

15.3.3 Effect of Termination for Any Reason. In the event of termination of this Agreement for any reason, in each case without
prejudice and in addition to any contractual remedy either Party may have with respect to this Agreement, in addition to the rights and obligations set forth in Section 15.3.1 or Section 15.3.2, the following shall apply:

 (a) Except as expressly set forth in this Agreement, all licenses granted to either Party under this Agreement, including all sublicenses
thereunder, shall immediately terminate. 
 (b) Within thirty (30) days following the expiration of this Agreement or termination of
this Agreement in its entirety, each Party shall, at the request of the other Party, (i) deliver to the other Party, or certify the destruction of any and all tangible Confidential Information of the other Party in such Party’s possession,
(ii) to the extent practicable, remove Confidential Information of the other Party from all databases and systems and in those instances where removal is not practicable, segregate or otherwise indicate that such Confidential Information is
restricted, and/or (iii) treat all Confidential Information of the other Party contained in lab notebooks in accordance with such Party’s then current procedure for the status of the project and properly note that such Confidential
Information contained in such lab notebooks is restricted. Notwithstanding the foregoing, the Parties may retain such Confidential Information of the other Party as is necessary or useful for the practice of the rights granted to it under
Section 15.3.1 or Section 15.3.2. 

  
 45 

 (c) With respect to termination of this Agreement as it relates to only certain countries in the
Territories, this Agreement shall continue in full force and effect with respect to the Development, Manufacture and Commercialization of the Licensed Products in all other countries of the Territory, without any modification to this Agreement
unless otherwise mutually agreed between the Parties. 
 15.3.4 Survival. Termination or expiration shall not relieve either Party
from obligations which are expressly indicated to survive termination or expiration of this Agreement. 
 15.3.5 Other Remedies.
Termination or expiration of this Agreement for any reason shall not release any Party from any liability or obligation that has accrued prior to such termination or expiration, nor affect the survival of any provision hereof to the extent it is
expressly stated or by its nature is intended to survive termination or expiration. Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any
rights, remedies, or claims, whether for damages or otherwise, that a Party may have hereunder with respect to the period prior to such termination or expiration or that may arise out of or in connection with such termination or expiration. 

ARTICLE XVI. 
 DISPUTE
RESOLUTION 
 16.1 Resolution by Executive Officers. The Parties shall attempt to resolve any and all disputes, claims or
controversies arising out of or relating to this Agreement (each, a “Dispute”) by the JSC as set forth in Section 3.1.1(f). Any Dispute that cannot be resolved by the JSC shall be referred to the Executive Officers who
shall promptly commence good faith negotiations to resolve the Dispute. Any Dispute that is not resolved through by negotiation of the Executive Officers within thirty (30) days after referral of the Dispute to the Executive Officers shall be
submitted for final and binding arbitration pursuant to Section 16.2. 
 16.2 Arbitration. 

16.2.1 To the extent not resolved pursuant to Section 16.1, and subject to any applicable public order rule as regards the
arbitrability of the subject-matter of a Dispute, any Dispute arising out of or relating to this Agreement (for the avoidance of doubt, including the Work Plan) or the alleged breach, termination, enforcement, interpretation or validity hereof,
including the determination of the scope or applicability of this Agreement to arbitrate, shall be determined solely by arbitration in English in Paris, France. Notwithstanding anything to the contrary in this Agreement, each Party may apply to any
court of law or equity of competent jurisdiction for temporary injunctive or other interim relief, pending completion of arbitration, to enforce or prevent any violation of this Agreement. 

  
 46 

 16.2.2 Any arbitration hereunder shall be finally settled under the Rules of Arbitration of the
International Chamber of Commerce (“ICC”) by one or more arbitrators appointed in accordance with the Rules then in force. 

16.2.3 Except as may be required to confirm or enforce a final award, or as may be required by applicable Law, neither a Party nor an
arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. 

ARTICLE XVII. 
 GENERAL
PROVISIONS 
 17.1 Assignment. This Agreement is binding upon and will inure to the benefit of the Parties and their respective
permitted assignees or successors in interest, including those that may succeed by assignment, transfer or otherwise to the ownership of the assets necessary to the conduct of the business to which this Agreement relates. This Agreement is personal
to the Parties “intuitu personae”, which means that it may not be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however, that either Party may, without such
consent, assign or otherwise transfer this Agreement, together with all of its rights and obligations hereunder, to any of its Affiliates, or to a successor in interest in connection with the transfer or sale of all or substantially all of its
business to which this Agreement relates (including, with respect to DBV, by transfer or sale of all or substantially all of the Licensed Patents), or in the event of its merger or consolidation or similar business combination transaction. Any
purported assignment in violation of the preceding sentences in this Section shall be void. Any permitted assignee or successor shall assume and be bound by all obligations of its assignor or predecessor under this Agreement. 

17.2 Allocation of Costs. Without limiting NESTEC’s payment obligations under ARTICLE VIII of this Agreement, each of
NESTEC and DBV shall be solely responsible for all costs and expenses it incurs in connection with their activities under this Agreement except as otherwise expressly set forth in this Agreement. Each of NESTEC and DBV accepts to bear all future
liabilities and risks that may be imposed on it (including unforeseeable as of the Effective Date, within the meaning of new Article 1195 of the French Civil Code) resulting from the terms and conditions of this Agreement. 

17.3 Headings; Rules of Construction. Headings are inserted for convenience and shall not affect the meaning or interpretation of this
Agreement. Each Party agrees that this Agreement shall be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted. Except as otherwise explicitly specified to the contrary
in this Agreement, (a) the words “hereof,” “herein,” “hereby,” “hereunder” and words of similar import shall refer to this Agreement as a whole and not to any particular section or subsection of this
Agreement and reference to a particular section of this Agreement shall include all subsections thereof, (b) references to a section, exhibit or schedule means a section of, or exhibit or schedule to, this Agreement, (c) definitions shall
be equally applicable to both the singular and plural forms of the terms defined, and references to the masculine, feminine or neuter gender shall include each 

  
 47 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 
other gender, (d) the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation,”
(e) references to a rule, statute or regulation (including ICC rules and procedures) include all rules and regulations thereunder and any successor statute, rule or regulation, in each case as amended or otherwise modified from time to time,
(f) references to a particular Governmental Authority include any successor agency or body to such Governmental Authority and (g) references to “days” means calendar days, unless specified as Business Days. 

17.4 No Implied Waiver. No waiver of any default hereunder by either Party or any failure to enforce, or delay in enforcing, any rights
hereunder shall be deemed to constitute a waiver of any subsequent default with respect to the same or any other provision hereof. 
 17.5
Notices. Any notice or other communication given by one Party to the other Party under this Agreement must be in writing and shall be sufficient if (a) delivered personally or (b) sent by registered or certified mail, return receipt
requested, reputable overnight business courier, email or fax, in each case properly addressed to the receiving Party as set forth below. The effective date of any notice or other communication given hereunder shall be the actual date of receipt by
the receiving Party. 
 If to DBV: 

DBV Technologies 
 177-181
avenue Pierre Brossolette 
 92120 Montrouge 

France 
 Fax: [***] 

Email: [***] 
 Attn :
Chief Executive Officer 
 with a copy (which copy shall not constitute legal notice to DBV) to: 

DBV Technologies 
 177-181
avenue Pierre Brossolette 
 92120 Montrouge 

France 
 Fax: [***] 

Email: [***] 
 Attn :
General Counsel 
 If to NESTEC: 

NESTEC S.A. 
 55, Avenue
Nestlé, 
 CH-1800 Vevey 

Switzerland 
 Email : [***]

 Attn : General Counsel of Nestlé Healthcare Science S.A. 

  
 48 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 with a copy (which copy shall not constitute legal notice to NESTEC) to: 

Nestlé Health Sciences SA 

55, Avenue Nestlé, 

CH-1800 Vevey, 
 Switzerland 

Email : [***] 

Attn : Head of Global Business Development & Licensing 

Any Party may change its notification address by giving notice to the other Party in the manner herein provided. 

17.6 Severability. Whenever possible, each term and provision of this Agreement shall be interpreted in such manner as to be valid and
effective under applicable Laws, but, if any term or provision of this Agreement is held to be invalid or unenforceable under applicable Laws, such term or provision shall be invalid and ineffective only to the extent of such invalidity or
unenforceability, without invalidating or making unenforceable the remainder of this Agreement. In the event of such invalidity or unenforceability, the Parties shall use reasonable efforts to seek and agree on an alternative valid and enforceable
provision that preserves the original purpose and intent of the Agreement. 
 17.7 Entire Agreement. This Agreement constitutes the
entire agreement between the Parties and shall cancel and supersede any and all prior and contemporaneous negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof,
including the Confidentiality Agreement and that certain non-binding term sheet exchanged by the Parties prior to the Effective Date. 

17.8 Amendment; Waiver. Any amendment or modification to this Agreement shall only be made in writing and shall only be valid when
signed by an authorized representative of each Party. No term or provision of this Agreement, including the Parties’ respective obligations, may be waived except by a writing signed by the Party against which such waiver is sought to be
enforced. 
 17.9 Counterparts. This Agreement may be executed in more than one counterpart (including by electronic transmission),
each of which shall be deemed an original, but all of such counterparts taken together shall constitute one and the same agreement. 
 17.10
Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer, or legal representative of the other Party for any purpose. Neither Party shall be entitled to enter into any contracts in the name of, or on behalf of the
other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 

  
 49 

 17.11 Further Actions. Each Party agrees to execute, acknowledge, and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purpose and intent of this Agreement. 

17.12 Compliance with Laws. Each Party will comply with all applicable Laws in performing its obligations and exercising its rights
hereunder, including all applicable Laws relating to the export, re-export or other transfer of any Know-How transferred pursuant to this Agreement. 

17.13 Governing Law. Any dispute, claim or controversy arising under or related to this Agreement, including the construction, validity
and performance of this Agreement, shall be governed in all respects by the substantive laws of France; provided, however, that any issue relating to the interpretation, construction, validity, enforceability or infringement of Patent Rights shall
be determined according to the patent laws of the country (or countries) in which the relevant Patent (or Patents) issued. 
 17.14 Force
Majeure. 
 17.14.1 No failure or delay by either Party in the performance of any obligation hereunder (other than any obligation to
make a payment to the other Party) shall be deemed a breach of this Agreement nor create any liability for any damages, increased cost or losses which the other Party may sustain by reason of such failure or delay of performance, if the same shall
arise from any event beyond that Party’s control, that is, an unpredictable and irresistible event (hereinafter “Force Majeure”). Said Force Majeure event may include earthquake, storm, flood, fire, other acts of nature, epidemic,
war, riot, hostility, public disturbance, cessation of transport, act of public enemies, prohibition or act by a Governmental Authority or public agency, work stoppage; provided, however, that the failing or delaying Party shall
(a) without undue delay, notify the other Party in writing of the applicable failure or delay and (b) continue to take all commercially reasonable actions within its power to comply with its obligations hereunder as fully as possible and
to mitigate possible damages. 
 17.14.2 Should an event of Force Majeure continue for more than ninety (90) days, the Parties shall
promptly discuss their further performance under this Agreement and whether to modify or terminate this Agreement in view of the effect of the event of Force Majeure. Any such modification or termination of this Agreement shall be effective only
upon mutual written agreement of the Parties. 
 [Signature page follows.] 

  
 50 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

									
	For DBV TECHNOLOGIES	 		 	For NESTEC S.A.
			
	/s/ Pierre-Henri Benhamou	 		 	/s/ Greg Behar
					
	By:	 	Dr Pierre-Henri BENHAMOU	 		 	By:	 	Greg Behar
		 	 Chairman and CEO
  
	 		 	  
 Authorized
Signatory

  
 51 

 List of Exhibits: 

Exhibit 1.47: Licensed Patents as of the Effective Date 

Exhibit 1.56: NESTEC Patents as of the Effective Date 

Exhibit 1.60: Calculation of the Net Sales 
 Exhibit
1.98: Viaskin® Patents as of the Effective Date 
 Exhibit 1.101: Work Plan 

Exhibit 2.1.2: List of FTE members and range of their applicable rates 

Exhibit 5.2.1: Key terms of the Supply agreement 

  
 52 

 EXHIBIT 1.47: 

Licensed Patents as of the Effective Date 

1) International (PCT) patent application No. PCT/FR2002/00804 filed on 6 March 2002 (published under No. WO 02/071950) claiming priority from the French
patent application No. FR 0103382 filed on 13 March 2001 and all patents and patent applications deriving from the said PCT application and/or based on the same priority (Viaskin I) 

2) French patent No. 2 866 553 filed on 19 February 2004 (Applicator) 

3) International (PCT) patent application No. PCT/FR2005/050397 filed on 31 May 2005 (published under No. WO 2006/128981) and all patents and patent
applications deriving from the said PCT application and/or based on the same priority (Microcontours) 
 4) US patent No. 7 635 488 filed on
26 April 2006, International (PCT) patent application No. PCT/EP2007/053975 filed on 24 April 2007 (published under No. WO 2007/122226) claiming priority from the US patent application No. US 11/411,531 and all patents and
patent applications deriving from the said PCT application and/or based on the same priority (Viaskin II) 
 5) French patent No. FR 2 926 466
filed on 23 January 2008, International (PCT) patent application number PCT/FR2009/050094 filed on 23 January 2009 (published under No. WO 2009/095591) claiming priority from the French patent application No. FR 0850406, and all
patents and patent applications deriving from the said PCT application and/or based on the same priority (Electrospray) 

  
 53 

 EXHIBIT 1.56: 

NESTEC Patents as of the Effective Date 

International (PCT) patent application No. PCT/EP16/053673, filed on 22 February 2016, claiming priority from US provisional application No. USP
61/118875, and all patents and patent applications derived from the said PCT application and/or based on the same priority. 

  
 54 

 [***] = TWO (2) PAGES OF CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT 1.60, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
 EXHIBIT 1.60: 

Calculation of the Net Sales 

for the purpose of determining the Sales Milestones (section 8.2.2) 

and the Royalty Payment (Section 8.3.1) 

“Net Sales” shall mean the gross amount of sales of Licensed Product invoiced by NESTEC, its Affiliates or Sublicensees to Third Parties,
less: 
 [***]. 

  
 55 

 EXHIBIT 1.98: 

Viaskin® Patents as of the Effective Date 

1) International (PCT) patent application No. PCT/FR2002/00804 filed on 6 March 2002 (published under No. WO 02/071950) claiming priority from the French
patent application No. FR 0103382 filed on 13 March 2001 and all patents and patent applications deriving from the said PCT application and/or based on the same priority (Viaskin I) 

2) International (PCT) patent application No. PCT/FR2005/050397 filed on 31 May 2005 (published under No. WO 2006/128981) and all patents and patent
applications deriving from the said PCT application and/or based on the same priority (Microcontours) 
 3) US patent No. 7 635 488 filed on
26 April 2006, International (PCT) patent application No. PCT/EP2007/053975 filed on 24 April 2007 (published under No. WO 2007/122226) claiming priority from the US patent application No. US 11/411,531 and all patents and
patent applications deriving from the said PCT application and/or based on the same priority (Viaskin II) 
 4) French patent No. FR 2 926 466
filed on 23 January 2008, International (PCT) patent application No. PCT/FR2009/050094 filed on 23 January 2009 (published under No. WO 2009/095591) claiming priority from the French patent application No. FR 0850406, and all
patents and patent applications deriving from the said PCT application and/or based on the same priority (Electrospray) 

  
 56 

 EXHIBIT 1.101: 

Work Plan 

  
 57 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

[***] 

  
 58 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

EXHIBIT 2.1.2: 

List of FTE members and range of applicable rates 
  

	 	•	 	Project manager 

  

	 	•	 	[***] clinical development manager 

  

	 	•	 	[***] regulatory manager 

  

	 	•	 	[***] engineer for the industrial development 

  

	 	•	 	[***] technician for the industrial development 

  

	 	•	 	[***] engineer for pharmaceutical development 

  

	 	•	 	[***] technician for pharmaceutical development 

 Also potentially incremental staffing at certain points in the
development horizon 
 FTE rate would range between €[***] and [***], plus, with respect to the grant of equity compensation to the corresponding
employees, the share-based payment expenses recognized in DBV’s accounts in accordance with IFRS2 as well as all taxes, social security contributions and other payments accrued by DBV in relation thereto. All employees are eligible to receive
long-term incentives in the form of equity compensation plans. 

  
 59 

 EXHIBIT 5.2.1: 

Key Terms of the Supply Agreement 

  
 60 

 [***] = TWENTY (20) PAGES OF CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT 5.2.1, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
 [***] 

  
 61 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

 KEY TERMS OF THE SUPPLY AGREEMENT 

 

	1.	Any capitalized terms in this Exhibit 5.2.1 shall have the meaning given to such terms in ARTICLE I of the Agreement. 

  

	2.	The terms and conditions for the Supply agreement and corresponding quality agreement shall be negotiated and executed in accordance with ARTICLE V of the Agreement and with the following key terms and
conditions. 

  

	3.	NESTEC undertakes to purchase solely from DBV the Licensed Product manufactured by DBV’s Contract Manufacturer Organisation in the Territories for a [***] period as from the First Commercial Sale of a
Licensed Product. 

  

	4.	The purchasing price of the Licensed Product will be [***]. 

  

	5.	DBV shall continuously aim to improve the cost-efficiency of the Licensed Products. The Supply agreement will detail the conditions of DBV’s regular reporting on costs and NESTEC audit rights on costs.

  

	6.	Each NESTEC and DBV will accept to bear all future liabilities and risks that may be imposed on it (including unforeseeable as of the date hereof, within the meaning of new Article 1195 of the French Civil Code)
resulting from the terms and conditions of the Supply agreement. 

  

	7.	Notwithstanding the above, in the event of a Manufacturing Transfer Event, Section 5.2.2 of the Agreement shall apply and NESTEC shall have the right to terminate the Supply agreement and/or to manufacture
and or have the Licensed Product manufactured by any Third Party and DBV shall provide all cooperation and assistance, within the limit of [***] following termination, requested by NESTEC that are necessary to continue to manufacture and/or have
manufactured the Licensed Product; [***]. 

  

	8.	Payment shall be made within 30 (thirty) days calculated as from the date of invoice then end of month. Under Article L 441-6 of the French Commercial Code, any delayed payment may entail a penalty amounting to
three (3) times France’s legal interest rate. 

  

	9.	The Supply agreement will detail agreed annual minimum units to be supplied by DBV to NESTEC, together with supply chain specifications (safety stocks, order planning, purchase order, delivery date, batch release
procedure, quarantine clause, penalties, freight and transfer of risks). 

  

	10.	DBV shall ensure that all manufacturing equipment necessary to supply the Licensed Product is made available for production launch at a date to be agreed between the Parties and for routine production for the
duration of the Supply agreement and maintained in good order. 

  
 62 

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

	11.	DBV shall permit, and shall procure that any CMO permits, NESTEC, Regulatory Authorities and any Third Party nominated by NESTEC to carry out audits at the manufacturing facilities. 

 

	12.	DBV shall keep and provide NESTEC with an updated list of all CMO and subcontractors used for the purpose the Supply agreement. Each CMO and subcontractors shall be subject to NESTEC’s prior approval.

  

	13.	DBV shall warrant that the supplied Licensed Products shall conform the specifications of the quality agreement and be of good materials and workmanship and free from defects. 

 

	14.	NESTEC will be provided by the CMO with a release certificate as a warranty that: 

(i) Licensed Product Manufacturing processes shall be conducted in accordance with the technical agreements and Good Manufacturing
Practice and any other regulations applicable; and 
 (ii) Licensed Products shall conform to the specifications of the quality
agreement and comply with the relevant Regulatory Approval, including the pharmaceutical specifications hereof resulting from module 3.2. 
  

	15.	DBV will warrant continuity of supply of Licensed Products to NESTEC. DBV shall use every efforts to anticipate the risk of a discontinuity and if it does anticipate such risk, DBV undertakes to immediately give
NESTEC notice thereof. 

 DBV shall then undertake, at NESTEC’s specific prior request, to: 

(i) use every effort to introduce to NESTEC a new manufacturer meeting the requirements of the Regulatory Approval for the purpose of agreement
by competent Regulatory Authorities, within a reasonable period helping avoid over [***] inventory shortage; and 
 (ii) bear [***] related
to appointment of such new manufacturer, including the costs of validation of a new manufacturing site and the costs of registration and related change costs, unless continuity of supply has been interrupted because of a breach by NESTEC of its
obligations under the Supply agreement. 
 In the event DBV fails to fulfil its obligations herein under, NESTEC shall reserve to terminate
the Supply agreement and/or, should a Manufacturing Transfer Event occur, elect to request application of the Manufacturing Transfer Event provisions as specified in paragraph 7 above. 

 

	16.	ARTICLE XVI and ARTICLE XVII of the Agreement shall apply mutadis mutandis to the Supply agreement. 

  
 63

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]